Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,5.599999904632568,5.670000076293945,5.559999942779541,5.559999942779541,12252,0.0,0.0,,,,,,,,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-06-28,5.559999942779541,5.559999942779541,5.059999942779541,5.25,24239,0.0,0.0,,,,,,,0.0,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-06-29,5.25,5.650000095367432,5.010000228881836,5.389999866485596,10996,0.0,0.0,,,,,,,32.72118507220425,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-06-30,5.380000114440918,5.380000114440918,5.190000057220459,5.230000019073486,29783,0.0,0.0,,,,,,,23.326916232662597,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-01,5.230000019073486,5.460000038146973,5.110000133514404,5.409999847412109,4521,0.0,0.0,,,,,,,43.11382322926137,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-04,5.409999847412109,5.409999847412109,5.110000133514404,5.269999980926514,4271,0.0,0.0,,,,,,,35.45078413178631,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-05,5.25,5.25,5.099999904632568,5.099999904632568,10556,0.0,0.0,,,,,,,28.76496613605312,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-06,5.059999942779541,5.110000133514404,4.065000057220459,5.019999980926514,27747,0.0,0.0,,,,,,,26.255537985319492,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-07,5.079999923706055,6.449999809265137,5.079999923706055,5.800000190734863,16297,0.0,0.0,,,,,,,61.51146376563454,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-08,5.789999961853027,5.789999961853027,5.150000095367432,5.650000095367432,23716,0.0,0.0,5.3679999828338625,,,5.25335531735036,,,55.96982561619117,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-11,5.639999866485596,5.639999866485596,5.25,5.579999923706055,28237,0.0,0.0,5.369999980926513,,,3.910613473471727,,,53.545465908514856,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-12,5.570000171661377,5.570000171661377,5.0,5.449999809265137,12437,0.0,0.0,5.389999961853027,,,1.1131697186781129,,,49.27659422755289,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-13,5.420000076293945,5.420000076293945,5.099999904632568,5.380000114440918,12860,0.0,0.0,5.388999986648559,,,-0.1670044948958792,,,47.09918103610824,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-14,5.380000114440918,5.559999942779541,5.070000171661377,5.21999979019165,17348,0.0,0.0,5.387999963760376,,,-3.1180433314530984,,,42.47876149951527,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-15,5.099999904632568,5.699999809265137,5.019999980926514,5.300000190734863,4033,0.0,0.0,5.376999998092652,,,-1.4320217107141917,,,45.36476499858909,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-18,5.289999961853027,5.409999847412109,5.050000190734863,5.119999885559082,8503,0.0,0.0,5.361999988555908,,,-4.513243258361169,,,40.44747518274267,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-19,5.269999980926514,5.269999980926514,5.0,5.070000171661377,30119,0.0,0.0,5.359000015258789,,,-5.3927942297916935,,,39.17713857332215,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-20,5.079999923706055,5.150000095367432,5.0,5.039999961853027,8611,0.0,0.0,5.361000013351441,,,-5.987689809717784,,,38.397889653116536,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-21,5.039999961853027,5.389999866485596,4.614999771118164,4.980000019073486,25948,0.0,0.0,5.278999996185303,,,-5.663951076489471,,,36.820481130016354,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-22,4.559999942779541,5.150000095367432,4.335000038146973,5.039999961853027,20741,0.0,0.0,5.217999982833862,,,-3.4112690986281704,,,39.4971659055494,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-25,5.099999904632568,5.150000095367432,4.949999809265137,5.099999904632568,23082,0.0,0.0,5.169999980926514,,,-1.3539666644525012,,,42.13717388363629,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-26,5.099999904632568,5.320000171661377,4.659999847412109,5.130000114440918,29936,0.0,0.0,5.138000011444092,,,-0.155700603062579,,,43.46548955293966,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-27,5.130000114440918,5.130000114440918,4.75,4.974999904632568,16205,0.0,0.0,5.097499990463257,,,-2.403140481802259,,,38.54244673969454,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-28,4.974999904632568,5.079999923706055,4.934999942779541,5.0,18782,0.0,0.0,5.075500011444092,,,-1.48753839570203,,,39.72820785663921,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-07-29,4.989999771118164,5.25,4.855000019073486,5.079999923706055,15050,0.0,0.0,5.053499984741211,,,0.5243878311043665,,,43.485820077014296,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-01,5.0,5.139999866485596,4.710000038146973,5.070000171661377,6762,0.0,0.0,5.048500013351441,,,0.4258722046761666,,,43.12391028796836,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-02,5.050000190734863,5.050000190734863,4.75,4.864999771118164,28278,0.0,0.0,5.027999973297119,,,-3.2418497025581146,,,36.43023292706544,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-03,4.864999771118164,4.909999847412109,4.699999809265137,4.804999828338623,5967,0.0,0.0,5.0044999599456785,,,-3.9864148906741317,,,34.731030496159576,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-04,4.789999961853027,4.804999828338623,4.449999809265137,4.505000114440918,27490,0.0,0.0,4.956999969482422,,,-9.118415530042842,,,27.75922583355164,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-05,4.505000114440918,4.800000190734863,4.125,4.644999980926514,37410,0.0,0.0,4.917499971389771,,,-5.541433493618177,,,34.37925858980458,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-08,4.590000152587891,4.635000228881836,4.21999979019165,4.474999904632568,13814,0.0,0.0,4.854999971389771,,,-7.826983913419575,,,30.700287556268947,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-09,4.46999979019165,4.474999904632568,4.050000190734863,4.255000114440918,46449,0.0,0.0,4.76749997138977,,,-10.749865968000288,,,26.71593249637756,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-10,4.119999885559082,4.409999847412109,4.010000228881836,4.409999847412109,12520,0.0,0.0,4.710999965667725,,,-6.389304191237715,,,33.285395512328876,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-11,3.9700000286102295,4.409999847412109,3.9700000286102295,4.409999847412109,31266,0.0,0.0,4.6519999504089355,,,-5.202065898034953,,,33.285395512328876,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-12,4.409999847412109,5.090000152587891,4.389999866485596,4.559999942779541,16028,0.0,0.0,4.599999952316284,,,-0.8695654337257411,,,39.38409011813375,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-15,4.550000190734863,4.550000190734863,4.150000095367432,4.46999979019165,22551,0.0,0.0,4.539999914169312,,,-1.5418529801992145,,,37.18749846078791,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-16,4.465000152587891,5.090000152587891,4.275000095367432,5.090000152587891,10110,0.0,0.0,4.562499952316284,,,11.561648345964489,,,55.57100589259011,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-17,4.985000133514404,4.985000133514404,4.565000057220459,4.900000095367432,28289,0.0,0.0,4.571999979019165,,,7.174105814817448,,,50.67622750053489,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-18,5.0,5.0,4.760000228881836,4.994999885559082,12497,0.0,0.0,4.620999956130982,,,8.093484808020614,,,52.90964708051644,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-19,4.994999885559082,5.0,4.59499979019165,4.949999809265137,17910,0.0,0.0,4.651499938964844,5.038749969005584,,6.417282042719358,-7.685438500080322,,51.715090810434795,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-22,5.199999809265137,5.199999809265137,4.5,4.835000038146973,17323,0.0,0.0,4.687499952316284,5.02062497138977,,3.146668529730918,-6.635130506098581,,48.689727729831624,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-23,4.849999904632568,5.489999771118164,4.574999809265137,4.949999809265137,4564,0.0,0.0,4.756999921798706,5.013124966621399,,4.057176595316273,-5.109089570438313,,51.73072262880316,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-24,4.949999809265137,4.949999809265137,4.699999809265137,4.875,11950,0.0,0.0,4.803499937057495,5.000249969959259,,1.4884993000812663,-3.9348039414790863,,49.663457449173144,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-25,4.894999980926514,4.900000095367432,4.619999885559082,4.885000228881836,10640,0.0,0.0,4.850999975204468,4.991624975204468,,0.7008916481376545,-2.8172188555539406,,49.95065485218934,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-26,4.885000228881836,5.130000114440918,4.880000114440918,4.949999809265137,28406,0.0,0.0,4.889999961853027,4.980124974250794,,1.2269907541956966,-1.8096937900905823,,51.872743986914756,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-29,4.945000171661377,4.945000171661377,4.300000190734863,4.84499979019165,33927,0.0,0.0,4.9274999618530275,4.969499969482422,,-1.67428051344626,-0.8451556069487016,,48.62418352307744,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-30,4.329999923706055,4.704999923706055,4.320000171661377,4.610000133514404,11078,0.0,0.0,4.8794999599456785,4.957249975204467,,-5.523103363941302,-1.5684102203375774,,42.24723953107154,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-08-31,4.610000133514404,4.610000133514404,4.324999809265137,4.59499979019165,11778,0.0,0.0,4.848999929428101,4.946624970436096,,-5.238196389629719,-1.9735686774610774,,41.86977205949802,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-01,4.494999885559082,4.590000152587891,4.324999809265137,4.519999980926514,16443,0.0,0.0,4.801499938964843,4.914624965190887,,-5.862750424173043,-2.3018038411329695,,39.947923984971354,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-02,4.449999809265137,4.525000095367432,4.324999809265137,4.519999980926514,16463,0.0,0.0,4.758499956130981,4.886374962329865,,-5.0120831649305275,-2.6169708052431515,,39.947923984971354,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-05,5.230000019073486,5.230000019073486,4.300000190734863,4.590000152587891,11477,0.0,0.0,4.733999967575073,4.861624968051911,,-3.0418212077205515,-2.625151082519177,,42.7903929648234,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-06,4.704999923706055,4.704999923706055,4.5,4.5,2329,0.0,0.0,4.688999986648559,4.837874972820282,,-4.0307098994821295,-3.077280562398146,,40.15846705945928,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-07,4.539999961853027,5.150000095367432,4.5,4.885000228881836,6906,0.0,0.0,4.690000009536743,4.825499975681305,,4.157787184404587,-2.8079984836272,,53.37099591983337,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-08,4.614999771118164,4.84499979019165,4.519999980926514,4.690000057220459,1609,0.0,0.0,4.670499992370606,4.8122499823570255,,0.41751557395797556,-2.9456073667434692,,47.6343013506606,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-09,4.800000190734863,4.800000190734863,4.550000190734863,4.739999771118164,6288,0.0,0.0,4.649499988555908,4.798249971866608,,1.9464411826004675,-3.100088244315323,,49.143748717941925,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-12,4.550000190734863,4.65500020980835,4.5,4.59499979019165,2423,0.0,0.0,4.624499988555908,4.785124969482422,,-0.637911091734482,-3.3567562383618896,,45.085033515768664,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-13,4.59499979019165,4.59499979019165,4.449999809265137,4.574999809265137,6184,0.0,0.0,4.620999956130982,4.772749960422516,,-0.9954587167830135,-3.1795087852894794,,44.53864244713333,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-14,4.454999923706055,4.59499979019165,4.380000114440918,4.59499979019165,7453,0.0,0.0,4.620999956130982,4.761624956130982,,-0.5626523736455633,-2.953298533496087,,45.25316330123808,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-15,4.454999923706055,4.534999847412109,4.21999979019165,4.534999847412109,15485,0.0,0.0,4.622499942779541,4.750499951839447,,-1.8929171757829644,-2.694453433482149,,43.44487008180065,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-16,4.199999809265137,4.53000020980835,4.199999809265137,4.5,6727,0.0,0.0,4.620499944686889,4.736999952793122,,-2.607941697422854,-2.4593626613303936,,42.380993994194675,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-19,4.099999904632568,4.494999885559082,4.0,4.0,49077,0.0,0.0,4.5614999294281,4.709499955177307,,-12.309545941360971,-3.1425847151034714,,30.783598505400832,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-20,3.950000047683716,4.375,3.7249999046325684,3.7899999618530273,12738,0.0,0.0,4.4904999256134035,4.67599995136261,,-15.599598605152803,-3.967066460194271,,27.393093000907456,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-21,3.7899999618530273,4.0,3.6549999713897705,3.9000000953674316,11920,0.0,0.0,4.391999912261963,4.649124956130981,,-11.202181847065253,-5.53061159455259,,31.64030285269331,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-22,3.6649999618530273,4.34499979019165,3.6600000858306885,4.335000038146973,4418,0.0,0.0,4.356499910354614,4.632499957084656,,-0.49351251348680814,-5.957907162156465,,45.27366116826156,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-23,4.324999809265137,4.324999809265137,3.700000047683716,3.9149999618530273,15690,0.0,0.0,4.273999929428101,4.60337495803833,,-8.399625023463924,-7.155077125209641,,37.49772789472219,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-26,3.9200000762939453,4.389999866485596,3.680000066757202,3.9649999141693115,6447,0.0,0.0,4.210999941825866,4.575749951601028,,-5.841843530159029,-7.971371111472951,,38.84435807141749,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-27,4.079999923706055,4.324999809265137,3.8299999237060547,4.090000152587891,6864,0.0,0.0,4.162499976158142,4.556374961137772,,-1.7417375131655068,-8.644481376951365,,42.197304123035146,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-28,4.090000152587891,4.34499979019165,4.0,4.275000095367432,4881,0.0,0.0,4.13050000667572,4.543124967813492,,3.4983679568616477,-9.082403941363726,,46.84246054288847,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-29,3.809999942779541,4.349999904632568,3.809999942779541,4.21999979019165,602,0.0,0.0,4.099000000953675,4.53599995970726,,2.9519343549603287,-9.634037976970966,,45.66746203856402,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-09-30,4.210000038146973,4.210000038146973,3.700000047683716,4.085000038146973,10853,0.0,0.0,4.057500004768372,4.521999961137771,,0.6777580615226877,-10.272002661683521,,42.82774309886379,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-03,4.085000038146973,4.085000038146973,3.799999952316284,3.9700000286102295,1146,0.0,0.0,4.054500007629395,4.509374964237213,,-2.0841035604923146,-10.087317205052226,,40.51647802343847,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-04,4.0,4.0,3.7300000190734863,3.9000000953674316,13509,0.0,0.0,4.065500020980835,4.500499963760376,,-4.0708381443686505,-9.665591518327187,,39.13213860949951,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-05,3.75,4.0,3.440000057220459,3.75,23683,0.0,0.0,4.050500011444091,4.483999967575073,,-7.418837442169433,-9.667706495667453,,36.27215924396272,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-06,3.8499999046325684,3.930000066757202,3.615000009536743,3.7750000953674316,7285,0.0,0.0,3.994500017166138,4.468124973773956,,-5.495053720250786,-10.60008301889049,,37.09731008709894,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-07,3.690000057220459,4.0,3.690000057220459,3.9800000190734863,8098,0.0,0.0,4.001000022888183,4.453624975681305,,-0.5248688751453127,-10.163068405279912,,43.55165373154,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-10,3.9800000190734863,4.114999771118164,3.615000009536743,3.994999885559082,2963,0.0,0.0,4.004000020027161,4.4417499780654905,,-0.22477858199455603,-9.855348909777726,,44.004400276383734,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-11,4.025000095367432,4.699999809265137,3.555000066757202,3.9700000286102295,16773,0.0,0.0,3.9920000076293944,4.413749974966049,,-0.5511016777835478,-9.555366065788515,,43.3799075886105,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-12,3.994999885559082,3.994999885559082,3.9749999046325684,3.9749999046325684,33,0.0,0.0,3.9619999885559083,4.390624970197678,,0.3281149953106978,-9.762277228211351,,43.55244480351541,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-13,3.9700000286102295,3.9700000286102295,3.700000047683716,3.9700000286102295,373,0.0,0.0,3.937000012397766,4.364999973773957,,0.838202085561213,-9.80526836077261,,43.4099869003522,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-14,3.7049999237060547,4.5,3.7049999237060547,4.039999961853027,12771,0.0,0.0,3.9325000047683716,4.342249977588653,,2.733628911743323,-9.436351544362836,,46.069671554239854,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-17,3.7049999237060547,4.400000095367432,3.7049999237060547,4.28000020980835,9109,0.0,0.0,3.9635000228881836,4.328374981880188,,7.98537113895445,-8.429837075564734,,54.044582106099995,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-18,4.28000020980835,4.28000020980835,3.805000066757202,4.28000020980835,5651,0.0,0.0,4.001500034332276,4.311624991893768,,6.959894366777052,-7.192762778408475,,54.044582106099995,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-19,4.394999980926514,4.394999980926514,3.9000000953674316,4.385000228881836,4060,0.0,0.0,4.065000057220459,4.299374997615814,,7.872082832888931,-5.451372362851021,,57.25200043040186,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-20,4.0,4.300000190734863,3.740000009536743,4.300000190734863,5898,0.0,0.0,4.117500066757202,4.28474999666214,,4.432304092745086,-3.9033766272297608,,53.968239270955074,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-21,3.765000104904175,4.389999866485596,3.765000104904175,4.389999866485596,4868,0.0,0.0,4.158500051498413,4.2707499980926515,,5.566906627878188,-2.628342718360252,,56.793976056542945,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-24,4.389999866485596,4.389999866485596,4.099999904632568,4.260000228881836,998,0.0,0.0,4.185000085830689,4.256125009059906,,1.7921180767732334,-1.6711192241255834,,51.84342354593112,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-25,4.260000228881836,4.260000228881836,4.0,4.099999904632568,3668,0.0,0.0,4.198000073432922,4.24337500333786,,-2.334448953932823,-1.0693122778270974,,46.47403111388757,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-26,4.099999904632568,4.400000095367432,3.7100000381469727,4.385000228881836,11043,0.0,0.0,4.2390001058578495,4.238125014305115,,3.4442113559334366,0.020648082578526496,,55.34567630115078,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-27,4.099999904632568,4.5,3.9549999237060547,4.5,5625,0.0,0.0,4.292000102996826,4.237625014781952,,4.8462230198443175,1.2831500669643794,,58.34577144448913,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-28,3.950000047683716,4.5,3.950000047683716,4.485000133514404,5675,0.0,0.0,4.336500120162964,4.236750018596649,,3.4244208286995197,2.3544013956092504,,57.80029417084213,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-10-31,4.485000133514404,4.485000133514404,3.7699999809265137,4.150000095367432,11647,0.0,0.0,4.323500108718872,4.2257500171661375,,-4.012952676965507,2.313200997589717,,47.189362228014154,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-01,4.0,4.0,3.799999952316284,3.9800000190734863,6677,0.0,0.0,4.293500089645386,4.212750017642975,,-7.301736672323972,1.9168018910267728,,42.88671981430178,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-02,3.9800000190734863,3.9800000190734863,3.8299999237060547,3.9800000190734863,6358,0.0,0.0,4.253000068664551,4.1901250123977665,,-6.418999416493938,1.5005532312460619,,42.88671981430178,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-03,3.9800000190734863,4.744999885559082,3.9800000190734863,4.300000190734863,10314,0.0,0.0,4.253000068664551,4.180375015735626,,1.1051051331177335,1.7372855941285645,,52.367880641810146,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-04,4.599999904632568,4.599999904632568,4.099999904632568,4.400000095367432,8081,0.0,0.0,4.254000091552735,4.171875023841858,,3.432063955631135,1.9685409376249223,,54.88816179455271,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-07,4.40500020980835,4.699999809265137,4.114999771118164,4.630000114440918,9646,0.0,0.0,4.291000080108643,4.172750031948089,,7.90025700311085,2.8338636931325434,,60.11534684833828,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-08,4.625,4.625,4.284999847412109,4.610000133514404,4429,0.0,0.0,4.342000102996826,4.173625040054321,,6.172271399362848,4.034264250540179,,59.470046319599824,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-09,4.610000133514404,4.894999980926514,4.284999847412109,4.684999942779541,2801,0.0,0.0,4.372000074386596,4.175875043869018,,7.159191744452553,4.696621150231186,,61.15403006161761,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-10,4.670000076293945,4.75,4.320000171661377,4.75,18537,0.0,0.0,4.397000074386597,4.181250047683716,,8.028199218592203,5.159940789056602,,62.60421279575872,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-11,4.75,5.5,4.425000190734863,4.900000095367432,17483,0.0,0.0,4.4385000705719,4.191250050067902,,10.397657259382846,5.89919516970819,,65.77911583226569,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-14,4.900000095367432,4.900000095367432,4.454999923706055,4.789999961853027,3842,0.0,0.0,4.502500057220459,4.211000049114228,,6.385339277709004,6.922346347812263,,61.645808488912415,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-15,5.0,5.0,4.599999904632568,4.849999904632568,10441,0.0,0.0,4.589500045776367,4.2375000476837155,,5.67599643224614,8.306784522281248,,63.01109394105272,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-16,4.449999809265137,4.994999885559082,4.409999847412109,4.835000038146973,12269,0.0,0.0,4.6750000476837155,4.260875046253204,,3.4224596541454813,9.719247735149414,,62.412948808768505,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-17,5.0,5.0,4.545000076293945,4.795000076293945,2800,0.0,0.0,4.724500036239624,4.272375047206879,,1.492222235443876,10.582521057656857,,60.75664424321712,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-18,4.784999847412109,5.139999866485596,4.394999980926514,5.139999866485596,8654,0.0,0.0,4.798500013351441,4.303000044822693,,7.116804255162222,11.515221086853716,,68.51705608646579,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-21,4.505000114440918,4.894999980926514,4.505000114440918,4.784999847412109,2151,0.0,0.0,4.813999986648559,4.3235000431537625,,-0.6024125325484129,11.344973715716751,,56.20134318547356,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-22,4.784999847412109,4.800000190734863,4.784999847412109,4.800000190734863,835,0.0,0.0,4.832999992370605,4.341250044107437,,-0.6828016074453888,11.32738135944602,,56.55668094966131,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-23,5.130000114440918,5.130000114440918,4.215000152587891,5.119999885559082,4526,0.0,0.0,4.876499986648559,4.362375038862228,,4.993333324663278,11.785436676265743,,63.3818050718388,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-24,5.090000152587891,5.090000152587891,4.514999866485596,4.699999809265137,13474,0.0,0.0,4.871499967575073,4.374375039339066,,-3.5204795125002484,11.364478897335681,,51.86468728706633,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-25,5.090000152587891,5.090000152587891,4.610000133514404,4.704999923706055,12332,0.0,0.0,4.851999950408936,4.389875036478043,,-3.029679064413255,10.527063073340956,,51.97656605492244,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-28,4.710000038146973,4.954999923706055,4.710000038146973,4.949999809265137,3664,0.0,0.0,4.867999935150147,4.414375030994416,,1.6844674446870285,10.276084405396436,,57.223006586370246,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-29,4.800000190734863,4.960000038146973,4.65500020980835,4.945000171661377,2768,0.0,0.0,4.877499961853028,4.440500032901764,,1.3839100017687138,9.841232422324616,,57.08595056892052,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-11-30,4.954999923706055,4.960000038146973,4.614999771118164,4.949999809265137,5602,0.0,0.0,4.888999938964844,4.470500028133392,,1.2476962786219337,9.361366920876451,,57.19635661473164,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-01,4.925000190734863,4.945000171661377,4.650000095367432,4.894999980926514,4193,0.0,0.0,4.898999929428101,4.498500025272369,,-0.08164826616059699,8.902965475286011,,55.50463045187819,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-02,4.400000095367432,4.775000095367432,4.400000095367432,4.764999866485596,1537,0.0,0.0,4.861499929428101,4.5181250214576725,,-1.9849853819468706,7.599942594320823,,51.618360282070014,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-05,4.264999866485596,5.0,4.264999866485596,4.800000190734863,26902,0.0,0.0,4.862999963760376,4.538250029087067,,-1.295491949311,7.155840524252412,,52.581011741581904,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-06,4.800000190734863,4.954999923706055,4.53000020980835,4.795000076293945,5859,0.0,0.0,4.862499952316284,4.558875030279159,,-1.3881722711418198,6.660084341433083,,52.42054590304751,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-07,4.885000228881836,4.885000228881836,4.880000114440918,4.880000114440918,1984,0.0,0.0,4.838499975204468,4.5815000355243685,,0.8577067159062304,5.609515173793619,,54.93814501511283,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-08,4.869999885559082,4.869999885559082,4.599999904632568,4.800000190734863,1444,0.0,0.0,4.84850001335144,4.602250039577484,,-1.000305712756975,5.350643091016489,,52.141692913631246,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-09,4.795000076293945,4.795000076293945,4.014999866485596,4.784999847412109,6351,0.0,0.0,4.8565000057220455,4.620875036716461,4.667291661103566,-1.472256938653206,5.099141767162287,-0.9945087592004118,51.61120716585756,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-12,4.5,4.78000020980835,4.179999828338623,4.764999866485596,14229,0.0,0.0,4.838000011444092,4.6330000281333925,4.6606666604677836,-1.5088909629147873,4.424778373966311,-0.5936196331967278,50.86810720819257,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-13,4.349999904632568,4.599999904632568,4.349999904632568,4.599999904632568,886,0.0,0.0,4.803499984741211,4.641000020503998,4.655249993006389,-4.2364959041340775,3.5013997741712175,-0.3061054191246193,45.09899449202976,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-14,4.105000019073486,4.849999904632568,4.105000019073486,4.590000152587891,2040,0.0,0.0,4.767500019073486,4.646125018596649,4.648583328723907,-3.723122512332797,2.6123920469427624,-0.052882995816550885,44.767621175057755,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-15,4.590000152587891,4.795000076293945,4.590000152587891,4.795000076293945,1062,0.0,0.0,4.757500028610229,4.658500015735626,4.644958329200745,0.7882301094734994,2.125147848882636,0.2915351565104681,52.476760043440066,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-16,4.230000019073486,4.784999847412109,4.230000019073486,4.699999809265137,7370,0.0,0.0,4.751000022888183,4.666250014305115,4.6390416622161865,-1.0734627105314758,1.8162337706563902,0.58650803484982,49.05940422529467,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-19,4.599999904632568,4.684999942779541,4.235000133514404,4.664999961853027,4044,0.0,0.0,4.7375,4.676375007629394,4.633999995390574,-1.5303438131287068,1.3071020239155688,0.9144370367063176,47.823761471456095,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-20,4.664999961853027,4.864999771118164,4.324999809265137,4.855000019073486,5272,0.0,0.0,4.743499994277954,4.695250010490417,4.631958329677582,2.3505855366297843,1.027633963681037,1.366413000896762,54.520436291179514,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-21,4.795000076293945,4.795000076293945,4.349999904632568,4.684999942779541,11872,0.0,0.0,4.723999977111816,4.70275000333786,4.629166662693024,-0.8255722802970764,0.4518627134947448,1.5895591152043091,48.519944976284634,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-22,4.590000152587891,4.949999809265137,4.364999771118164,4.820000171661377,5153,0.0,0.0,4.725999975204468,4.710750007629395,4.620999995867411,1.9890012050379233,0.3237269553759982,1.9422205549068994,52.94858377799062,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-23,4.820000171661377,4.989999771118164,4.289999961853027,4.989999771118164,13548,0.0,0.0,4.746499967575073,4.723374998569488,4.615499993165334,5.130091756168106,0.4895857096374696,2.3372333563838477,57.864226458015246,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-27,4.900000095367432,4.900000095367432,3.6649999618530273,4.53000020980835,43782,0.0,0.0,4.723000001907349,4.732875001430512,4.60674999554952,-4.0863813682205725,-0.20864695391655438,2.7378304879326714,44.359436599739325,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-28,4.900000095367432,4.900000095367432,4.284999847412109,4.599999904632568,3708,0.0,0.0,4.723000001907349,4.7483749985694885,4.5996666630109155,-2.604279001166796,-0.534393274957944,3.2330241831313353,46.40914362001592,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-29,4.900000095367432,4.900000095367432,4.0,4.744999885559082,15985,0.0,0.0,4.738499975204467,4.767499995231629,4.5943749944369,0.13717232011453456,-0.6082856854990352,3.768194825288683,50.47871488385119,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2022-12-30,4.255000114440918,4.59499979019165,4.25,4.53000020980835,13307,0.0,0.0,4.711999988555908,4.773249995708466,4.588624997933706,-3.862474091459748,-1.2831929441706713,4.023536415765031,45.01969078136596,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-02,4.53000020980835,4.695000171661377,4.099999904632568,4.579999923706055,10692,0.0,0.0,4.7,4.777749991416931,4.582624995708466,-2.553193112637138,-1.6273348659223672,4.257930681458671,46.46953758236119,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-03,4.40500020980835,4.704999923706055,4.400000095367432,4.59499979019165,7403,0.0,0.0,4.692999982833863,4.7768749833107,4.578249994913737,-2.0882206051710863,-1.7558550468638405,4.338447848361884,46.92174339844167,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-04,4.400000095367432,4.599999904632568,4.235000133514404,4.550000190734863,2518,0.0,0.0,4.6625,4.775374984741211,4.573916661739349,-2.4128645418796006,-2.3636884035679118,4.404503577580526,45.67516048789202,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-05,4.545000076293945,4.545000076293945,4.204999923706055,4.534999847412109,4396,0.0,0.0,4.647499990463257,4.771624982357025,4.569708327452342,-2.4206593498009616,-2.601314905356508,4.418589556179698,45.24365930905303,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-09,4.994999885559082,4.994999885559082,4.414999961853027,4.59499979019165,3080,0.0,0.0,4.624999952316284,4.767749977111817,4.56649999221166,-0.6486521607337388,-2.994075307657106,4.407094826308908,47.384810637745716,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-10,4.320000171661377,4.885000228881836,4.320000171661377,4.599999904632568,7567,0.0,0.0,4.585999965667725,4.760249972343445,4.562833325068156,0.30527560116990426,-3.6605221929120226,4.326624121698333,47.568810056717936,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-11,4.599999904632568,4.599999904632568,4.349999904632568,4.46999979019165,6477,0.0,0.0,4.579999923706055,4.752249968051911,4.557583324114481,-2.401749680061002,-3.624599831739624,4.27126900582234,43.326455619415775,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-12,4.46999979019165,4.46999979019165,4.300000190734863,4.434999942779541,9570,0.0,0.0,4.563499927520752,4.741874969005584,4.551791656017303,-2.8158209002322065,-3.761698540150234,4.17601084041265,42.23436731856811,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-13,4.434999942779541,4.894999980926514,4.349999904632568,4.514999866485596,64955,0.0,0.0,4.540499925613403,4.73387496471405,4.547958322366079,-0.5616134686834657,-4.084920715947292,4.08791438201324,45.60909681930541,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-16,4.514999866485596,4.599999904632568,4.364999771118164,4.494999885559082,10159,0.0,0.0,4.536999893188477,4.726374959945678,4.543749988079071,-0.9257220325803948,-4.0067719629121035,4.019256612836094,44.90283154416078,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-17,4.489999771118164,4.894999980926514,4.355000019073486,4.570000171661377,19934,0.0,0.0,4.535999917984009,4.712124967575074,4.539499990145365,0.749564688979954,-3.7376990381836355,3.802731089425132,48.1456286533266,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-18,4.570000171661377,4.869999885559082,4.324999809265137,4.489999771118164,11875,0.0,0.0,4.52549991607666,4.704749965667725,4.534666653474172,-0.7844469255735234,-3.8099803581299345,3.7507346226485203,45.09668735488687,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-19,4.84499979019165,4.84499979019165,4.364999771118164,4.460000038146973,424,0.0,0.0,4.5164999008178714,4.696249961853027,4.531291655699412,-1.2509656572928851,-3.8275232897575755,3.6404257039189454,43.972135036736276,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-20,4.485000133514404,4.485000133514404,4.355000019073486,4.434999942779541,6045,0.0,0.0,4.506499910354615,4.679124963283539,4.528208323319753,-1.586596449514792,-3.6892593013328314,3.332811328193144,43.009615521203116,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-23,4.429999828338623,4.739999771118164,4.304999828338623,4.389999866485596,6882,0.0,0.0,4.485999917984008,4.67137496471405,4.527249987920126,-2.139992270475894,-3.9683187098081536,3.18349941307609,41.25893742552326,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-24,4.550000190734863,4.550000190734863,4.300000190734863,4.400000095367432,2544,0.0,0.0,4.465999937057495,4.663749969005584,4.525208322207133,-1.4778289883619729,-4.240150807017948,3.0615529039529106,41.82563811272002,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-25,4.400000095367432,4.625,4.300000190734863,4.400000095367432,9042,0.0,0.0,4.458999967575073,4.649999976158142,4.52458332379659,-1.3231637729687404,-4.10752708736301,2.7718939709196118,41.825638112720014,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-26,4.400000095367432,4.400000095367432,4.210000038146973,4.355000019073486,11872,0.0,0.0,4.450999975204468,4.635249972343445,4.525416656335195,-2.1568177188446613,-3.9749743430951514,2.427032124312634,39.82073280466657,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-27,4.380000114440918,4.385000228881836,4.150000095367432,4.210000038146973,12879,0.0,0.0,4.420499992370606,4.61674997806549,4.5237499912579855,-4.761903734576121,-4.250825507711755,2.0558162362470216,34.14168393276884,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-30,4.210000038146973,4.210000038146973,3.6500000953674316,4.005000114440918,8141,0.0,0.0,4.371500015258789,4.5944999814033505,4.520374993483226,-8.383847638993421,-4.853628622204238,1.6397973182974104,28.050780136283308,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-01-31,4.0,4.005000114440918,3.805000066757202,4.005000114440918,15733,0.0,0.0,4.315000009536743,4.5754999876022335,4.515749994913737,-7.184238572669361,-5.693366381189826,1.3231466036825668,28.050780136283308,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-01,4.644999980926514,4.650000095367432,4.0,4.0,6108,0.0,0.0,4.266000032424927,4.5554999828338625,4.511833329995473,-6.235349986008417,-6.354954483587662,0.9678250423854501,27.909931971638272,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-02,4.130000114440918,4.460000038146973,3.9100000858306885,4.400000095367432,12671,0.0,0.0,4.2600000381469725,4.5456249833107,4.506083329518636,3.2863862903005234,-6.283513184928399,0.8775171451675733,49.6783180139389,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-03,4.400000095367432,4.400000095367432,3.8499999046325684,4.385000228881836,2351,0.0,0.0,4.255000066757202,4.533249986171723,4.50179166396459,3.055232904466407,-6.137978718652114,0.6987956030694756,49.07981588159987,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-06,4.369999885559082,4.369999885559082,4.025000095367432,4.03000020980835,10985,0.0,0.0,4.2190001010894775,4.513999986648559,4.49375,-4.4797318500258445,-6.535221232424192,0.4506255721515223,37.54975515498694,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-07,4.46999979019165,4.46999979019165,3.9149999618530273,4.090000152587891,9057,0.0,0.0,4.188000106811524,4.496624994277954,4.486583336194356,-2.3400179494800466,-6.863478450152314,0.2238152583189326,40.11061418588607,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-08,4.0,4.0,3.75,3.7899999618530273,19847,0.0,0.0,4.127000093460083,4.47224999666214,4.4778750022252405,-8.165740828091774,-7.719825668505428,-0.12561774413767957,32.85590046978247,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-09,3.7899999618530273,3.7899999618530273,3.6649999618530273,3.7049999237060547,5334,0.0,0.0,4.06200008392334,4.449874997138977,4.467500003178914,-8.78877776566837,-8.716535036714951,-0.3945160834335958,31.137490258129574,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-10,3.7049999237060547,3.884999990463257,3.700000047683716,3.7300000190734863,3063,0.0,0.0,4.014000082015992,4.428374993801117,4.457958336671194,-7.075238095158907,-9.357267899967173,-0.6636074327282098,32.25968418936023,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-13,3.799999952316284,3.799999952316284,3.7300000190734863,3.799999952316284,4523,0.0,0.0,3.993500065803528,4.403499990701675,4.448916667699814,-4.845376494273573,-9.310773833629916,-1.0208480039168768,35.4324639497238,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-14,3.7950000762939453,3.799999952316284,3.700000047683716,3.799999952316284,14651,0.0,0.0,3.9730000495910645,4.380999994277954,4.439333335558573,-4.35439454103674,-9.31294100022325,-1.314011291140843,35.4324639497238,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-15,3.799999952316284,3.799999952316284,3.6600000858306885,3.799999952316284,1796,0.0,0.0,3.953000044822693,4.359374994039536,4.430625003576279,-3.8704804141552045,-9.321862647110404,-1.6081254784422498,35.4324639497238,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-16,3.6500000953674316,3.7850000858306885,3.4000000953674316,3.634999990463257,35480,0.0,0.0,3.8765000343322753,4.32887499332428,4.422500002384186,-6.229847587518897,-10.450173767771735,-2.1170154665784606,31.13874092757716,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-17,3.7799999713897705,3.7899999618530273,3.0999999046325684,3.7899999618530273,66966,0.0,0.0,3.8170000076293946,4.306499993801117,4.415791670481364,-0.7073630003248562,-11.366538648004655,-2.475018860396867,38.658740537141,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-20,3.7899999618530273,3.7899999618530273,3.390000104904175,3.5450000762939453,10753,0.0,0.0,3.768499994277954,4.274624991416931,4.407666671276092,-5.9307395070550175,-11.840219859174342,-3.0184151793094554,32.59885816592221,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-21,3.430000066757202,3.5399999618530273,3.384999990463257,3.5399999618530273,12349,0.0,0.0,3.713499975204468,4.238374996185303,4.39950000445048,-4.672142574657957,-12.383874042604582,-3.6623481782517358,32.486933974604284,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-22,3.5399999618530273,3.700000047683716,3.450000047683716,3.684999942779541,18015,0.0,0.0,3.702999973297119,4.2172499895095825,4.391958336035411,-0.4860931851844159,-12.193965676487316,-3.977914478203733,39.024956053102365,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-23,3.694999933242798,3.799999952316284,3.609999895095825,3.7950000762939453,42478,0.0,0.0,3.7119999885559083,4.197124993801117,4.386083336671193,2.235993749836374,-11.55850745359518,-4.3081338945439684,43.495415768265076,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-24,3.7950000762939453,3.7950000762939453,3.484999895095825,3.7899999618530273,4650,0.0,0.0,3.717999982833862,4.173249995708465,4.376958334445954,1.9365244580847678,-10.908764472359827,-4.6541073314392065,43.339869684819085,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-27,3.7899999618530273,3.7899999618530273,3.5,3.765000104904175,10423,0.0,0.0,3.714499998092651,4.154124993085861,4.369250001509984,1.3595398260184353,-10.582854288807466,-4.923614083647706,42.521098903403654,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-02-28,3.6050000190734863,3.799999952316284,3.6050000190734863,3.799999952316284,3756,0.0,0.0,3.714499998092651,4.134624993801117,4.361416669686635,2.3017890501423106,-10.161139071580678,-5.1999543511125585,44.112938562495515,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-01,3.799999952316284,3.799999952316284,3.5199999809265137,3.6050000190734863,38778,0.0,0.0,3.6950000047683718,4.1098749995231625,4.353166671593984,-2.435723560994346,-10.09458912504457,-5.5888434885433895,37.827302503722855,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-02,3.5999999046325684,3.7799999713897705,3.549999952316284,3.7300000190734863,20348,0.0,0.0,3.7045000076293944,4.089374995231628,4.34612500667572,0.6883523118254787,-9.411584607697094,-5.907561587614711,43.39526425730627,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-03,3.694999933242798,3.7950000762939453,3.615000009536743,3.7850000858306885,2571,0.0,0.0,3.7040000200271606,4.070625001192093,4.339375009139379,2.186826818724854,-9.006601714910257,-6.193288374045968,45.699557715267225,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-06,3.7850000858306885,3.7850000858306885,3.4000000953674316,3.7149999141693115,10736,0.0,0.0,3.721000003814697,4.048625004291535,4.332541676362355,-0.16124938562844365,-8.092253546069484,-6.553120391658876,43.2844447880666,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-07,3.549999952316284,3.9700000286102295,3.115000009536743,3.509999990463257,29996,0.0,0.0,3.7180000066757204,4.021375006437301,4.324291676282883,-5.594406020414111,-7.544061403772265,-7.005000876952073,37.10075772910004,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-08,3.509999990463257,3.9749999046325684,3.4000000953674316,3.7950000762939453,7151,0.0,0.0,3.7290000200271605,4.004500013589859,4.3225833435853325,1.7699130038166138,-6.879760085597428,-7.358639607666688,48.18376209917102,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-09,3.7200000286102295,3.7200000286102295,3.4200000762939453,3.6050000190734863,19400,0.0,0.0,3.710000014305115,3.9837500154972076,4.3210416773955025,-2.8301885398050346,-6.871666146901196,-7.8057951549682025,42.772814331220665,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-10,3.5,3.505000114440918,3.359999895095825,3.5,6229,0.0,0.0,3.681000018119812,3.958375018835068,4.317708343267441,-4.9171425490039375,-7.007294644782955,-8.322315818127866,40.09324977252589,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-13,3.5,3.5,3.359999895095825,3.490000009536743,5217,0.0,0.0,3.6535000085830687,3.9332500219345095,4.310666676362356,-4.475160768091403,-7.112439122643162,-8.75541262555557,39.83728451794557,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-14,3.490000009536743,3.5850000381469727,3.424999952316284,3.450000047683716,3696,0.0,0.0,3.618500018119812,3.905250018835068,4.306791677077611,-4.656624833282422,-7.342679708911266,-9.323452081039846,38.77102788182212,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-15,3.315000057220459,3.450000047683716,3.315000057220459,3.450000047683716,6975,0.0,0.0,3.603000020980835,3.8792500257492066,4.3025000115235645,-4.246460516407892,-7.121221961325344,-9.837303536101102,38.77102788182212,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-16,3.4000000953674316,3.694999933242798,3.4000000953674316,3.694999933242798,7826,0.0,0.0,3.5995000123977663,3.860125023126602,4.299208343029022,2.6531440621225437,-6.751724598747224,-10.213120297237387,48.552646579220465,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-17,3.2049999237060547,3.484999895095825,3.2049999237060547,3.484999895095825,2879,0.0,0.0,3.5694999933242797,3.836375021934509,4.292625008026759,-2.36728108660842,-6.95643744640107,-10.628694219483652,42.31292784638675,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-20,3.2100000381469727,3.440000057220459,3.2100000381469727,3.440000057220459,6550,0.0,0.0,3.5420000076293947,3.812625026702881,4.2861250102519985,-2.8797275603961023,-7.098128380789652,-11.047274225939542,41.09419411256147,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-21,3.640000104904175,3.640000104904175,3.2850000858306885,3.5850000381469727,7227,0.0,0.0,3.549500012397766,3.792250025272369,4.281958343585332,1.0001415868491736,-6.4012132970364535,-11.436550265524643,46.44677303495929,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-22,3.359999895095825,3.5350000858306885,3.3450000286102295,3.4000000953674316,1249,0.0,0.0,3.5100000143051147,3.7672500252723693,4.277208344141642,-3.1339008116631026,-6.828588738244303,-11.922690639275189,41.29147574564276,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-23,3.3499999046325684,3.4000000953674316,3.2100000381469727,3.365000009536743,16418,0.0,0.0,3.4860000133514406,3.7425000250339506,4.272750010093053,-3.471027061137846,-6.853707681142451,-12.410039993132067,40.378353397472004,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-24,3.384999990463257,3.384999990463257,3.234999895095825,3.3299999237060547,2196,0.0,0.0,3.469000005722046,3.720500022172928,4.26925000945727,-4.0069207779392695,-6.759844508857052,-12.853545378432926,39.43910534055645,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-27,3.200000047683716,3.2950000762939453,3.0950000286102295,3.1649999618530273,17115,0.0,0.0,3.436500000953674,3.6995000183582305,4.2641666750113165,-7.900481275288867,-7.109069228259416,-13.242133802182753,35.27348669101774,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-28,3.200000047683716,3.2799999713897705,3.0450000762939453,3.2200000286102295,6828,0.0,0.0,3.4134999990463255,3.6798750162124634,4.257833341757457,-5.668667657540842,-7.2386974012043,-13.574000651383791,37.63797263219633,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-29,3.015000104904175,3.2300000190734863,3.015000104904175,3.2200000286102295,10774,0.0,0.0,3.390499997138977,3.660375016927719,4.251375009616216,-5.028755896552758,-7.372878968430334,-13.90138464265584,37.637972632196316,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-30,3.1050000190734863,3.2300000190734863,3.0999999046325684,3.194999933242798,15944,0.0,0.0,3.340499997138977,3.6302500128746034,4.244916675488154,-4.355637300427929,-7.981544375953009,-14.480064265168782,36.926849839185365,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-03-31,3.194999933242798,3.2249999046325684,3.115000009536743,3.200000047683716,3945,0.0,0.0,3.312000012397766,3.6006250083446503,4.238458343346914,-3.3816414340218115,-8.015969318603839,-15.048710718213556,37.18248588148373,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-03,3.200000047683716,3.509999990463257,3.109999895095825,3.5,3054,0.0,0.0,3.31800000667572,3.5873750030994414,4.234541676441828,5.485231855277313,-7.508972331885714,-15.283039412335727,50.219133805402116,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-04,3.440000057220459,4.269999980926514,3.2300000190734863,3.7899999618530273,7810,0.0,0.0,3.3384999990463258,3.57987499833107,4.232458343108495,13.524036631291803,-6.74255384328427,-15.418541468695004,59.06334294700569,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-05,3.990000009536743,3.990000009536743,3.4000000953674316,3.950000047683716,23180,0.0,0.0,3.393499994277954,3.583875000476837,4.229708341757457,16.39899968599146,-5.311987895045268,-15.26898048512427,62.9720504817544,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-06,3.950000047683716,3.950000047683716,3.4100000858306885,3.809999942779541,4195,0.0,0.0,3.437999987602234,3.5865000009536745,4.22579167286555,10.820243063373347,-4.140527347328971,-15.128329113260941,57.77393878786835,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-11,3.799999952316284,3.799999952316284,3.4100000858306885,3.6700000762939453,29684,0.0,0.0,3.472000002861023,3.5850000023841857,4.219833338260651,5.702767087262814,-3.152022299805096,-15.04403811687344,53.05735741416023,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-12,3.3299999237060547,3.6700000762939453,3.3299999237060547,3.490000009536743,7888,0.0,0.0,3.5045000076293946,3.5772500038146973,4.213083336750667,-0.4137536898583123,-2.033684984491543,-15.091876474163332,47.66894728553252,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-13,3.490000009536743,3.869999885559082,3.3399999141693115,3.509999990463257,12972,0.0,0.0,3.533500003814697,3.5700000047683718,4.20575000445048,-0.6650633458630282,-1.0224089889334007,-15.116209927108468,48.297251906921495,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-14,3.880000114440918,3.880000114440918,3.640000104904175,3.640000104904175,1777,0.0,0.0,3.575500011444092,3.5660000085830688,4.200583336750666,1.803946112533569,0.2664050150913436,-15.107028650417764,52.30569858933162,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-17,3.5999999046325684,3.5999999046325684,3.4000000953674316,3.490000009536743,1234,0.0,0.0,3.6050000190734863,3.562375009059906,4.195500004291534,-3.190014117289772,1.1965334897414088,-15.090573104135649,47.70948988347377,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-18,3.5199999809265137,3.700000047683716,3.4000000953674316,3.700000047683716,9111,0.0,0.0,3.655000019073486,3.560125011205673,4.1897916694482165,1.2311909268234922,2.6649347303588846,-15.028591107143729,53.826709608468605,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-19,3.990000009536743,3.990000009536743,3.309999942779541,3.7100000381469727,18824,0.0,0.0,3.6760000228881835,3.5642500102519987,4.183208336432775,0.924918798887161,3.135302302441008,-14.796258670410658,54.10206226430074,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-20,3.380000114440918,3.569999933242798,3.380000114440918,3.559999942779541,1564,0.0,0.0,3.653000020980835,3.5647500097751617,4.175500001509985,-2.5458548499083564,2.4756297345866165,-14.626990576313197,49.34820199914,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-21,3.559999942779541,3.559999942779541,3.4000000953674316,3.490000009536743,5354,0.0,0.0,3.6070000171661376,3.559875011444092,4.170000000794729,-3.2436930155968295,1.3237825926626894,-14.631294705859899,47.26117585843733,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-24,3.5,3.5,3.2799999713897705,3.5,1377,0.0,0.0,3.5760000228881834,3.552500009536743,4.1660000006357825,-2.1252802685051835,0.6615063557594395,-14.726356001090055,47.602099473101084,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-25,3.490000009536743,3.490000009536743,3.2899999618530273,3.430000066757202,1854,0.0,0.0,3.5520000219345094,3.5435000121593476,4.161416667699814,-3.434683401574501,0.23987610402128895,-14.848709102758844,45.39017049016123,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-26,3.25,3.4800000190734863,3.25,3.4100000858306885,3933,0.0,0.0,3.544000029563904,3.53462501168251,4.154000000158946,-3.781036755513354,0.26523373343445633,-14.910327117302266,44.75034999582867,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-27,3.299999952316284,3.450000047683716,3.2200000286102295,3.380000114440918,7684,0.0,0.0,3.53100004196167,3.5241250157356263,4.145500000317892,-4.276406845831214,0.1950846293858968,-14.989144482803429,43.75404909000291,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-04-28,3.5,4.5,3.440000057220459,4.5,115611,0.0,0.0,3.6170000314712523,3.546500015258789,4.144416666030883,24.412495461593302,1.9878758186701706,-14.427040014408604,70.32046612785865,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-02,4.5,5.199999809265137,4.300000190734863,4.400000095367432,11581,0.0,0.0,3.7080000400543214,3.563250017166138,4.1426666657129925,18.662352962190706,4.062303295891192,-13.986562166404267,67.26554044794509,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-03,4.5,4.949999809265137,3.8499999046325684,4.690000057220459,14069,0.0,0.0,3.8070000410079956,3.585875016450882,4.142708333333333,23.19411627793594,6.166556936386808,-13.441287005460223,71.17622515743706,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-04,4.690000057220459,4.690000057220459,4.210000038146973,4.389999866485596,8306,0.0,0.0,3.875000023841858,3.6027500152587892,4.139708332220713,13.290318438066556,7.556727706057968,-12.970921472476702,62.815860594202185,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-05,4.400000095367432,4.590000152587891,4.380000114440918,4.489999771118164,4843,0.0,0.0,3.9680000066757204,3.6272500097751617,4.13629166285197,13.155235976921292,9.39416902563274,-12.30671564214174,64.32029832621748,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-08,4.130000114440918,4.489999771118164,4.130000114440918,4.300000190734863,14606,0.0,0.0,4.049000024795532,3.6398750126361845,4.132208331425985,6.199065556982953,11.240084089124762,-11.914532843021028,59.402623086007516,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-09,4.300000190734863,4.960000038146973,4.300000190734863,4.739999771118164,5086,0.0,0.0,4.173000001907349,3.668250006437302,4.131291663646698,13.587341695462666,13.75996713921561,-11.208157034370899,65.90392690630212,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-10,4.730000019073486,4.730000019073486,3.9700000286102295,4.590000152587891,1690,0.0,0.0,4.289000010490417,3.695500010251999,4.129249997933706,7.017956198677096,16.060073023729938,-10.504328580220562,62.24439678256315,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-11,4.590000152587891,4.800000190734863,4.269999980926514,4.800000190734863,15790,0.0,0.0,4.428000020980835,3.7282500147819517,4.129291665554047,8.40108780468406,18.768859476281882,-9.71211731342512,65.16110080178288,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-12,4.800000190734863,4.900000095367432,4.489999771118164,4.489999771118164,31807,0.0,0.0,4.53899998664856,3.754250007867813,4.123874998092651,-1.0795376883571164,20.902976017477254,-8.963050296039398,58.033880992391644,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-15,4.550000190734863,4.789999961853027,4.340000152587891,4.639999866485596,3493,0.0,0.0,4.552999973297119,3.78400000333786,4.122666664918264,1.9108256907252814,20.32240933617668,-8.214747616203857,60.296810739108864,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-16,4.800000190734863,4.800000190734863,4.190000057220459,4.389999866485596,8662,0.0,0.0,4.551999950408936,3.80137500166893,4.11924999554952,-3.558877102113911,19.746143130063636,-7.716817241585858,54.97599165771035,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-17,4.210000038146973,4.369999885559082,4.170000076293945,4.289999961853027,11260,0.0,0.0,4.511999940872192,3.82150000333786,4.112333329518636,-4.920212365433919,18.068819493162895,-7.0722216045365895,52.96273646870785,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-19,4.539999961853027,4.539999961853027,4.289999961853027,4.300000190734863,10308,0.0,0.0,4.502999973297119,3.8430000066757204,4.108999999364217,-4.508100905308657,17.174081849464095,-6.47359437161486,53.14751581044805,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-22,4.300000190734863,4.309999942779541,3.809999942779541,4.21999979019165,18890,0.0,0.0,4.475999975204468,3.858875000476837,4.10495833158493,-5.719396479691075,15.992354628003591,-5.994782680609571,51.4076877049569,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-23,4.199999809265137,4.199999809265137,4.050000190734863,4.170000076293945,2094,0.0,0.0,4.462999963760376,3.878125,4.0984583338101706,-6.5650882779653665,15.081385044586662,-5.376005216218357,50.2994157231058,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-24,4.0,4.090000152587891,4.0,4.03000020980835,4692,0.0,0.0,4.392000007629394,3.8947500050067902,4.090833334128062,-8.242254034431026,12.767186648266971,-4.793236807900067,47.229168353697794,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-25,4.039999961853027,4.690000057220459,4.0,4.239999771118164,5511,0.0,0.0,4.3569999694824215,3.917500001192093,4.084916667143504,-2.685338516955652,11.218888785107564,-4.098410802306076,51.965470681019106,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-26,4.0,4.429999828338623,4.0,4.230000019073486,2451,0.0,0.0,4.299999952316284,3.9441250026226045,4.0793750007947285,-1.6279054423033408,9.0229125460538,-3.3154588177300472,51.72739141071205,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-29,4.059999942779541,4.380000114440918,4.059999942779541,4.380000114440918,2935,0.0,0.0,4.28899998664856,3.9731250047683715,4.07616666952769,2.1217096776786435,7.950290552174645,-2.527906072379959,55.05387909897071,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-30,4.380000114440918,4.690000057220459,4.170000076293945,4.400000095367432,11749,0.0,0.0,4.2650000095367435,4.0026250064373015,4.072833335399627,3.165300950265451,6.5550733000836265,-1.723820328028154,55.49425541409904,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-05-31,4.400000095367432,4.409999847412109,3.799999952316284,4.349999904632568,24748,0.0,0.0,4.26100001335144,4.031500005722046,4.069125000635783,2.088709012021956,5.6926704031664785,-0.9246458368287445,54.067995202067955,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-01,4.409999847412109,4.409999847412109,3.869999885559082,4.230000019073486,13020,0.0,0.0,4.255000019073487,4.05725000500679,4.063708333174388,-0.5875440631712154,4.873991344449216,-0.15892696124065667,50.70013752797251,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-02,4.230000019073486,4.230000019073486,3.9800000190734863,4.119999885559082,3809,0.0,0.0,4.236999988555908,4.072750002145767,4.058041663964589,-2.761390212717541,4.032901266309111,0.36244916635006336,47.76314117118445,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-05,4.050000190734863,4.050000190734863,3.5199999809265137,3.819999933242798,10359,0.0,0.0,4.197000002861023,4.073500001430512,4.0499999980131784,-8.98260827641721,3.031790877307982,0.5802469982435026,40.81830652422903,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-07,4.150000095367432,4.150000095367432,3.430000066757202,3.430000066757202,14348,0.0,0.0,4.123000001907348,4.060500001907348,4.0388749996821085,-16.80814782511657,1.539219307243978,0.5354214286637203,33.9145819961294,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-08,3.4200000762939453,3.440000057220459,2.609999895095825,3.4100000858306885,9966,0.0,0.0,4.0609999895095825,4.050500005483627,4.028958334525426,-16.030532020698445,0.2592268611712175,0.5346709786895436,33.60072849972693,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-09,3.4100000858306885,3.4100000858306885,3.059999942779541,3.200000047683716,5801,0.0,0.0,3.9570000171661377,4.038750004768372,4.017375000317892,-19.13065368204265,-2.0241408234160447,0.5320639584004112,30.417694538763,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-12,3.200000047683716,3.200000047683716,3.0,3.140000104904175,14739,0.0,0.0,3.8480000257492066,4.030000007152557,4.003583333889643,-18.399166219007082,-4.5161285627873875,0.6598257375911598,29.556190761974207,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-13,3.1500000953674316,3.1500000953674316,3.0,3.1500000953674316,17919,0.0,0.0,3.725000023841858,4.021000009775162,3.9906666696071627,-15.436239591788992,-7.361352529562792,0.7601070868438443,29.9124818880168,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-14,3.4700000286102295,3.4700000286102295,3.109999895095825,3.4000000953674316,10816,0.0,0.0,3.625000023841858,4.0150000095367435,3.9801250040531158,-6.206894537781716,-9.713573717771535,0.8762288985424628,38.31257196180668,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-15,3.4000000953674316,3.4000000953674316,3.1700000762939453,3.4000000953674316,2781,0.0,0.0,3.5300000429153444,4.0127500116825106,3.9680000046888986,-3.682718016075401,-12.030402276785573,1.127772352336993,38.312571961806675,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-16,3.4000000953674316,3.4000000953674316,3.0799999237060547,3.3399999141693115,2551,0.0,0.0,3.4410000324249266,4.0037500083446504,3.9567916711171467,-2.9351966667794156,-14.055572269668074,1.1867781053594288,37.075728121713354,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-19,3.490000009536743,3.490000009536743,3.4100000858306885,3.4100000858306885,1410,0.0,0.0,3.3700000524520872,3.9962500095367433,3.945041670401891,1.1869445921668855,-15.670940396375569,1.2980430477844713,39.52849116700355,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-20,3.4000000953674316,3.5,3.359999895095825,3.5,7378,0.0,0.0,3.3380000591278076,3.9947500109672545,3.932625005642573,4.853203654961039,-16.440326679676936,1.5797337716040545,42.62510448060725,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-21,3.5,3.5,3.5,3.5,63,0.0,0.0,3.3450000524520873,3.995000010728836,3.924041670560837,4.633780123091129,-16.270336834321178,1.8082973149940476,42.62510448060724,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-22,3.5,3.5,3.25,3.4600000381469727,935,0.0,0.0,3.3500000476837157,3.9940000116825103,3.9145416716734567,3.2835817581350186,-16.124185330873434,2.0298248600604465,41.528944570966395,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-26,4.590000152587891,4.590000152587891,3.4100000858306885,3.5999999046325684,5065,0.0,0.0,3.390000033378601,3.9982500076293945,3.905000005165736,6.194686406674567,-15.212904973179292,2.3879642084584507,46.695759928866615,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-27,3.5899999141693115,4.090000152587891,3.490000009536743,3.8399999141693115,5641,0.0,0.0,3.460000014305115,4.00900000333786,3.899250002702077,10.982656020032229,-13.694187791859628,2.8146438561192317,54.17197032997739,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-28,3.8399999141693115,4.0,3.259999990463257,4.0,11592,0.0,0.0,3.5450000047683714,4.024500000476837,3.8944166700045266,12.834978691667395,-11.914523435250409,3.3402519939439137,58.3645091093832,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-29,3.8499999046325684,3.8499999046325684,3.4100000858306885,3.549999952316284,4558,0.0,0.0,3.5599999904632567,4.000749999284745,3.885708338022232,-0.2808999487011569,-11.016684594145733,2.9606355200881334,45.70112406209888,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-06-30,3.809999942779541,3.809999942779541,3.430000066757202,3.549999952316284,1357,0.0,0.0,3.574999976158142,3.9794999957084656,3.877375002702077,-0.6993013708694874,-10.164594044139735,2.6338693816104803,45.701124062098884,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-03,3.549999952316284,3.7899999618530273,3.190000057220459,3.5,3340,0.0,0.0,3.590999984741211,3.949749994277954,3.868750003973643,-2.534112646279191,-9.082853599758673,2.0936992625813167,44.45810352195744,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-04,3.5,4.0,3.2799999713897705,3.319999933242798,6529,0.0,0.0,3.581999969482422,3.922999995946884,3.858125005165736,-7.314350599435702,-8.692327984113486,1.6815160393788486,40.21726518491478,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-05,3.740000009536743,3.740000009536743,3.4600000381469727,3.4600000381469727,1203,0.0,0.0,3.577999973297119,3.8972500026226045,3.848625006278356,-3.2979300176296458,-8.191674362964916,1.2634381438806201,44.640437060416176,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-06,3.240000009536743,3.390000104904175,3.240000009536743,3.319999933242798,2726,0.0,0.0,3.559999966621399,3.872749996185303,3.8390416741371154,-6.741574034518092,-8.075657604337124,0.8780400138730975,41.34603508738023,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-07,3.4200000762939453,3.4200000762939453,3.0999999046325684,3.299999952316284,2331,0.0,0.0,3.54399995803833,3.8367500007152557,3.829583340883255,-6.884876089476713,-7.630156841658975,0.1871394142410256,40.881878098518264,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-10,3.200000047683716,3.200000047683716,3.0199999809265137,3.190000057220459,4508,0.0,0.0,3.5029999732971193,3.80174999833107,3.8185416758060455,-8.935196073725809,-7.858223848624944,-0.4397405842488589,38.33298821445401,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-11,3.190000057220459,3.190000057220459,2.859999895095825,3.0899999141693115,3528,0.0,0.0,3.427999973297119,3.758999991416931,3.8068333427111307,-9.859978464431327,-8.805533888683078,-1.2565128806015458,36.127756347298615,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-12,3.0,3.140000104904175,2.9000000953674316,3.119999885559082,7186,0.0,0.0,3.339999961853027,3.7247499942779543,3.7947500069936115,-6.586828706785057,-10.329553205342341,-1.8446541296962728,37.29322593657257,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-13,3.119999885559082,3.119999885559082,2.9000000953674316,2.990000009536743,14823,0.0,0.0,3.283999967575073,3.683499997854233,3.782250008980433,-8.952495765565473,-10.845663920507194,-2.6108800553039053,34.366817926073935,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-14,2.990000009536743,2.990000009536743,2.990000009536743,2.990000009536743,150,0.0,0.0,3.227999973297119,3.6485000014305116,3.7700000087420147,-7.372985307595268,-11.525285130012938,-3.2228118575534337,34.366817926073935,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-17,2.799999952316284,2.799999952316284,2.630000114440918,2.799999952316284,14172,0.0,0.0,3.1579999685287476,3.6112500011920927,3.7563750088214873,-11.336289416723739,-12.551056628971265,-3.8634323593513007,30.332310017518537,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-18,2.490000009536743,2.7799999713897705,2.490000009536743,2.7799999713897705,4048,0.0,0.0,3.103999972343445,3.5732499957084656,3.7429583430290223,-10.438144453624533,-13.132303195371106,-4.534069892512315,29.93394993817313,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-19,2.5299999713897705,2.75,2.5299999713897705,2.740000009536743,17857,0.0,0.0,3.031999969482422,3.536250001192093,3.729125008980433,-9.630605636039123,-14.259456529931006,-5.172125024606601,29.11050467106881,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-20,2.740000009536743,2.740000009536743,2.5299999713897705,2.569999933242798,24595,0.0,0.0,2.956999969482422,3.496249997615814,3.7138750076293947,-13.08759013302806,-15.42366903113682,-5.8597828296998316,25.855192061767283,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-21,2.640000104904175,2.640000104904175,2.640000104904175,2.640000104904175,2859,0.0,0.0,2.890999984741211,3.46149999499321,3.6995833416779837,-8.6821128039371,-16.481294556613683,-6.435409739324556,29.358186730398714,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-24,2.640000104904175,2.640000104904175,2.5199999809265137,2.619999885559082,642,0.0,0.0,2.8339999675750733,3.4209999978542327,3.686333340406418,-7.551167412295405,-17.15872641471341,-7.197757718864685,28.93751788874023,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-25,2.619999885559082,2.700000047683716,2.430000066757202,2.6700000762939453,15441,0.0,0.0,2.7919999837875364,3.3819999992847443,3.6752083400885263,-4.369624219269873,-17.445299101773692,-7.978005970587218,31.577094169239544,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-26,2.700000047683716,2.9200000762939453,2.6600000858306885,2.75,6984,0.0,0.0,2.7549999952316284,3.3412499964237212,3.6647500058015186,-0.1814880305002701,-17.545828711397846,-8.82734180682659,35.69290433309348,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-27,2.990000009536743,2.990000009536743,2.799999952316284,2.9200000762939453,8672,0.0,0.0,2.7480000019073487,3.304249995946884,3.6557500064373016,6.259100228064546,-16.83437980545819,-9.61499035413996,43.47408736286494,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-28,2.890000104904175,2.9000000953674316,2.890000104904175,2.890000104904175,314,0.0,0.0,2.738000011444092,3.2677500009536744,3.6431666731834413,5.551500833629074,-16.211460159283238,-10.304680128777186,42.49685039653851,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-07-31,2.890000104904175,3.009999990463257,2.490000009536743,2.9000000953674316,8450,0.0,0.0,2.7480000257492065,3.234500002861023,3.630791672070821,5.531297969212509,-15.04096387947105,-10.914745460561583,42.95714312052311,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-01,2.559999942779541,2.8299999237060547,2.559999942779541,2.75,393,0.0,0.0,2.7450000286102294,3.200250005722046,3.6201250036557515,0.18214831831175027,-14.225450395994994,-11.59835634155446,38.0385282839552,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-02,2.75,2.9200000762939453,2.609999895095825,2.7899999618530273,1792,0.0,0.0,2.750000023841858,3.1745000064373015,3.609291668732961,1.4545431877956145,-13.372184020621699,-12.046454046987359,40.01109229085312,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-03,4.139999866485596,4.139999866485596,2.509999990463257,2.890000104904175,11840,0.0,0.0,2.7820000410079957,3.161000007390976,3.601791669925054,3.8821014487493573,-11.989875529794729,-12.238122105025862,44.746876863127184,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-04,2.700000047683716,2.7200000286102295,2.490000009536743,2.700000047683716,13426,0.0,0.0,2.7880000352859495,3.1432500064373015,3.593416670958201,-3.1563840203900155,-11.301995400423397,-12.527538711531063,38.524013016922716,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-07,2.6500000953674316,2.700000047683716,2.5,2.619999885559082,3418,0.0,0.0,2.7880000352859495,3.128750002384186,3.584166669845581,-6.0258302582710215,-10.890929823046786,-12.706347371982456,36.238817285807606,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-08,2.5199999809265137,2.680000066757202,2.490000009536743,2.5399999618530273,10533,0.0,0.0,2.7750000238418577,3.113749998807907,3.573666669925054,-8.46847062954197,-10.879164194162632,-12.869601829059011,34.06283166789353,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-09,2.990000009536743,2.990000009536743,2.369999885559082,2.5999999046325684,16894,0.0,0.0,2.7600000143051147,3.0999999940395355,3.5636666695276897,-5.797105392871874,-10.967741302843523,-13.010944021585674,37.11276571004749,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-10,2.5,2.7200000286102295,2.380000114440918,2.5999999046325684,6916,0.0,0.0,2.7279999971389772,3.079999989271164,3.553666669130325,-4.692085507355224,-11.428571212933099,-13.328956369874717,37.112765710047505,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-11,2.5,2.75,2.4000000953674316,2.609999895095825,3718,0.0,0.0,2.699999976158142,3.060249984264374,3.54512500166893,-3.3333363650757795,-11.771914384727271,-13.677233304221788,37.670047773681155,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-14,2.390000104904175,2.549999952316284,2.3499999046325684,2.5399999618530273,19391,0.0,0.0,2.6639999628067015,3.040249985456467,3.5347083350022634,-4.654654755438956,-12.375627808555839,-13.988660525380517,35.31116000682435,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-15,2.5399999618530273,2.5399999618530273,2.319999933242798,2.4600000381469727,12645,0.0,0.0,2.634999966621399,3.0164999842643736,3.5256666680177053,-6.6413635935947095,-12.647108225860313,-14.441713630279434,32.78444870681325,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-16,2.5,2.5,2.0,2.1700000762939453,61027,0.0,0.0,2.5729999780654906,2.9832499861717223,3.514250002304713,-15.662646918269338,-13.751781111467901,-15.109910102717524,25.626018120673706,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-17,2.1700000762939453,2.1700000762939453,2.0,2.119999885559082,8383,0.0,0.0,2.4959999561309814,2.9487499833106994,3.501208335161209,-15.064105656265008,-15.35396455251165,-15.779076791929105,24.627560289761576,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-18,2.049999952316284,2.0799999237060547,2.0,2.0799999237060547,20162,0.0,0.0,2.433999943733215,2.9142499804496764,3.4869166672229768,-14.543961717772397,-16.479369990159782,-16.423297182762305,23.827719270500978,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-21,2.119999885559082,2.119999885559082,2.0199999809265137,2.069999933242798,4719,0.0,0.0,2.378999948501587,2.875999981164932,3.4725833336512246,-12.988651616130245,-17.280947006892326,-17.17981384939203,23.621177206966905,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-22,2.069999933242798,2.5299999713897705,2.009999990463257,2.5299999713897705,12009,0.0,0.0,2.377999949455261,2.843249982595444,3.462291665871938,6.391927046479911,-16.363317892839028,-17.879535955287455,46.56607319723886,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-23,2.5299999713897705,2.5299999713897705,2.059999942779541,2.3499999046325684,3474,0.0,0.0,2.352999949455261,2.801999980211258,3.4502083321412402,-0.1274987202353029,-16.0242695905424,-18.787513376842856,41.333505517078265,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-24,2.440000057220459,2.440000057220459,2.0999999046325684,2.119999885559082,10344,0.0,0.0,2.3049999475479126,2.766249978542328,3.4378333310286204,-8.026033240722452,-16.674199171163494,-19.535075956848406,35.79814788899776,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-25,2.0299999713897705,2.5899999141693115,2.0299999713897705,2.3499999046325684,14276,0.0,0.0,2.278999948501587,2.736249977350235,3.426333330074946,3.115399637356863,-16.71082805422061,-20.14057846233007,43.89033318252884,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-28,2.3399999141693115,2.5999999046325684,2.180000066757202,2.4000000953674316,2847,0.0,0.0,2.2649999618530274,2.7087499797344208,3.4147916634877524,5.960270895720402,-16.38209584499566,-20.675981240747337,45.49858665853673,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-29,2.4000000953674316,2.5999999046325684,2.0999999046325684,2.5299999713897705,2495,0.0,0.0,2.271999955177307,2.688999980688095,3.4049166639645896,11.35563474042098,-15.507624711997236,-21.02596785563912,49.54764653509282,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-30,2.4700000286102295,2.4700000286102295,2.0199999809265137,2.2699999809265137,9372,0.0,0.0,2.281999945640564,2.6592499792575834,3.394583330551783,-0.5258529798379057,-14.186332107158318,-21.66196200505918,42.712925001463695,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-08-31,2.2699999809265137,2.4600000381469727,2.1500000953674316,2.3499999046325684,6784,0.0,0.0,2.3049999475479126,2.6349999785423277,3.382541662454605,1.952275839855323,-12.523720443328804,-22.099999305546167,45.2169845466359,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-01,2.25,2.2899999618530273,2.119999885559082,2.2899999618530273,10305,0.0,0.0,2.32599995136261,2.6097499787807465,3.3715833286444346,-1.5477209915027388,-10.87269009388793,-22.595714701495684,43.67504512195153,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-04,2.2799999713897705,2.2799999713897705,2.0,2.069999933242798,10785,0.0,0.0,2.32599995136261,2.581749975681305,3.359666661421458,-11.006019925746042,-9.906072498410866,-23.15457943113381,38.49191808327958,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-05,2.069999933242798,2.0999999046325684,1.9450000524520874,2.0999999046325684,9725,0.0,0.0,2.28299994468689,2.5569999754428863,3.348083327213923,-8.015770674029502,-10.715683746087565,-23.62794693133667,39.545503823354935,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-06,2.2300000190734863,2.2300000190734863,2.0,2.049999952316284,10919,0.0,0.0,2.252999949455261,2.5302499771118163,3.336416659752528,-9.010208685892735,-10.957416467325713,-24.16265007801836,38.36595177418126,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-07,2.359999895095825,2.359999895095825,2.0899999141693115,2.0899999141693115,58,0.0,0.0,2.2499999523162844,2.5077499747276306,3.3250833253065744,-7.111112957236254,-10.278138770167498,-24.580838150983336,39.91012482451331,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-08,2.259999990463257,2.259999990463257,1.9900000095367432,2.25,139,0.0,0.0,2.2399999618530275,2.489249974489212,3.3130416591962177,0.44643028202107654,-10.013056751655888,-24.865116996653374,45.763571665600615,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-11,2.0,2.4700000286102295,1.9950000047683716,2.3499999046325684,29484,0.0,0.0,2.234999942779541,2.477999973297119,3.3035833259423573,5.145412295179242,-9.80629673672889,-24.990541215113385,49.100796138189565,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-12,2.2799999713897705,2.390000104904175,2.109999895095825,2.299999952316284,6128,0.0,0.0,2.211999940872192,2.465999972820282,3.294083325068156,3.9783008045377044,-10.300082512069073,-25.138506544327942,47.52615460640396,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-13,2.109999895095825,2.369999885559082,2.109999895095825,2.299999952316284,2621,0.0,0.0,2.2149999380111693,2.4549999713897703,3.2833749910195666,3.8374725365200533,-9.77596888698689,-25.229375928594926,47.52615460640396,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-14,2.3399999141693115,2.3399999141693115,2.0799999237060547,2.190000057220459,10202,0.0,0.0,2.1989999532699587,2.445499974489212,3.273291657368342,-0.4092722255913037,-10.079739267661996,-25.289273597594946,43.931468782216754,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-15,1.9850000143051147,2.5799999237060547,1.9850000143051147,2.490000009536743,30146,0.0,0.0,2.21899995803833,2.4417499721050264,3.2659999907016752,12.21271097895766,-9.122556224487802,-25.237293966420527,54.12295069448498,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-18,2.490000009536743,2.490000009536743,2.130000114440918,2.369999885559082,7397,0.0,0.0,2.2489999532699585,2.4354999721050263,3.257999990383784,5.3801660650634675,-7.6575660427486705,-25.24555005237644,50.19283716488952,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-19,2.0899999141693115,2.1600000858306885,1.9850000143051147,2.140000104904175,9869,0.0,0.0,2.2529999732971193,2.422249972820282,3.2494583249092104,-5.015529060463172,-6.987305250172052,-25.456807546902162,43.65036451614161,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-20,2.119999885559082,2.430000066757202,2.059999942779541,2.430000066757202,5615,0.0,0.0,2.290999984741211,2.414249974489212,3.2428749918937685,6.067223175110254,-5.105104734404195,-25.552172670111396,52.12405725133213,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-21,2.3499999046325684,2.3499999046325684,2.1500000953674316,2.190000057220459,1843,0.0,0.0,2.3009999990463257,2.395999974012375,3.2342916587988535,-4.823987043540714,-3.964940567464239,-25.91886487744281,45.963841524508304,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-22,2.190000057220459,2.200000047683716,2.0,2.119999885559082,9257,0.0,0.0,2.287999987602234,2.3767499685287476,3.225333325068156,-7.342661842372286,-3.7340899169739608,-26.30994291176018,44.31864891612321,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-25,2.1600000858306885,2.1600000858306885,1.9500000476837158,1.9500000476837158,8684,0.0,0.0,2.2480000019073487,2.352999967336655,3.2149166584014894,-13.256225710444413,-4.462387033016192,-26.809923324525435,40.524996776932475,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-26,1.899999976158142,1.899999976158142,1.75,1.899999976158142,8513,0.0,0.0,2.2080000042915344,2.3317499667406083,3.201583324869474,-13.949276609363872,-5.307171189630395,-27.16884959301592,39.45524614370326,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-27,1.815000057220459,2.0899999141693115,1.815000057220459,1.9800000190734863,11170,0.0,0.0,2.176000010967255,2.3114999681711197,3.1864999920129775,-9.007352523249503,-5.861992605220484,-27.459595984153832,42.08928842737903,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-28,1.9600000381469727,1.9600000381469727,1.8350000381469727,1.9450000524520874,2269,0.0,0.0,2.1515000104904174,2.2878749668598175,3.169791658719381,-9.597952918032288,-5.960769637537455,-27.822544407094068,41.243877596838054,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-09-29,2.109999895095825,2.140000104904175,1.8550000190734863,2.140000104904175,23083,0.0,0.0,2.1165000200271606,2.273874968290329,3.1558749934037524,1.1103276472783867,-6.921002713772547,-27.947875849231497,47.56337755378919,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-02,2.1500000953674316,2.1500000953674316,1.9149999618530273,1.975000023841858,17875,0.0,0.0,2.0770000338554384,2.2577499717473986,3.141749992966652,-4.910929626912072,-8.005755294155433,-28.137185428447186,43.317859523097816,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-03,1.9800000190734863,2.0,1.9149999618530273,2.0,9130,0.0,0.0,2.0630000233650208,2.2442499727010725,3.1293333262205123,-3.0538062361366114,-8.07619256057773,-28.28344766290554,44.13156017960237,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-04,2.0,2.0,1.9149999618530273,1.9800000190734863,1569,0.0,0.0,2.0180000185966493,2.2287499755620956,3.116583326458931,-1.8830524862724654,-9.45597125188054,-28.487393337421,43.5924170877381,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-05,1.9900000095367432,2.0299999713897705,1.9850000143051147,2.0299999713897705,3356,0.0,0.0,2.0020000100135804,2.214499977231026,3.1031666586796445,1.398599462344666,-9.595844181635616,-28.637413944977556,45.388648872579736,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-06,1.909999966621399,2.1500000953674316,1.899999976158142,2.0299999713897705,25022,0.0,0.0,1.9930000185966492,2.1999999791383744,3.090999991695086,1.856495356140259,-9.409089204755189,-28.825623259484146,45.388648872579736,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-09,1.899999976158142,2.0199999809265137,1.8550000190734863,2.0199999809265137,1340,0.0,0.0,2.000000011920929,2.1869999796152113,3.076999991138776,0.9999984443187717,-8.550524437004505,-28.92427735088105,45.05585487593697,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-10,1.9199999570846558,2.559999942779541,1.9199999570846558,1.9950000047683716,2644,0.0,0.0,2.0095000147819517,2.1753749787807464,3.0627083241939546,-0.7215730234843278,-7.625120524819322,-28.972179244222907,44.18365787721717,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-11,2.4700000286102295,2.4700000286102295,2.0299999713897705,2.059999942779541,3169,0.0,0.0,2.0175000071525573,2.1726249754428864,3.0502083241939544,2.1065643358766053,-7.1399790596031,-28.77125938547091,47.053503985402145,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-12,2.2300000190734863,2.2300000190734863,1.9900000095367432,2.0299999713897705,12177,0.0,0.0,2.0259999990463258,2.1703749775886534,3.0380416572093965,0.19743200125012803,-6.652075334131073,-28.560065249985456,45.880977976735366,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-13,2.25,2.440000057220459,2.059999942779541,2.2699999809265137,25507,0.0,0.0,2.0389999866485597,2.175124979019165,3.0277916570504506,11.329082677319747,-6.258260729091006,-28.161339174238893,55.44611500696144,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-16,2.2699999809265137,2.2899999618530273,2.0799999237060547,2.240000009536743,9169,0.0,0.0,2.065499985218048,2.1793749809265135,3.017874989906947,8.448318836481317,-5.225121730086762,-27.78445137007772,54.1575842047916,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-17,2.2699999809265137,2.2699999809265137,2.069999933242798,2.069999933242798,7955,0.0,0.0,2.0724999785423277,2.167874979972839,3.0067083219687145,-0.12062944875339558,-4.3994696332399394,-27.89872685244803,47.430941123566534,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-18,2.3299999237060547,2.3299999237060547,2.059999942779541,2.1500000953674316,6177,0.0,0.0,2.0894999861717225,2.1628749847412108,2.9964583218097687,2.8954347736825983,-3.3924752510958287,-27.818953162181785,50.54398103882818,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-19,2.069999933242798,2.240000009536743,2.069999933242798,2.180000066757202,8505,0.0,0.0,2.1044999957084656,2.164374989271164,2.9771249890327454,3.587553870406162,-2.766387241559327,-27.299827946613693,51.69909390659773,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-20,2.1600000858306885,2.1600000858306885,2.0799999237060547,2.130000114440918,5288,0.0,0.0,2.1145000100135802,2.1588749945163728,2.9582083225250244,0.733038749299329,-2.0554679921490004,-27.020859955067948,49.618982686838734,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-23,2.130000114440918,2.1600000858306885,2.059999942779541,2.1600000858306885,719,0.0,0.0,2.128500020503998,2.152874994277954,2.9371249894301097,1.4799184882897876,-1.132205717412361,-26.701280945633975,50.89559781565598,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-24,1.9850000143051147,2.180000066757202,1.9850000143051147,2.1600000858306885,3261,0.0,0.0,2.1450000286102293,2.143624997138977,2.918541657924652,0.6993033575937934,0.06414515006530444,-26.551502483494133,50.89559781565598,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-25,2.200000047683716,2.430000066757202,2.0799999237060547,2.430000066757202,2466,0.0,0.0,2.1820000410079956,2.1476249992847443,2.901374993721644,11.365720489841998,1.6006072631255353,-25.97906151627962,61.16656088147974,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-26,2.4200000762939453,2.4200000762939453,2.109999895095825,2.190000057220459,7959,0.0,0.0,2.1980000495910645,2.1436250030994417,2.883791659275691,-0.3639668876301412,2.5365932200362753,-25.66644000774153,50.962487636423646,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-27,2.119999885559082,2.190000057220459,2.119999885559082,2.190000057220459,1787,0.0,0.0,2.190000057220459,2.1411250054836275,2.8625416616598764,0.0,2.2826809089454265,-25.201961803341145,50.962487636423646,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-30,2.190000057220459,2.2699999809265137,2.0799999237060547,2.2699999809265137,13189,0.0,0.0,2.193000054359436,2.14612500667572,2.8432083268960318,3.5111684750764325,2.1841713571160546,-24.51749010531799,53.93342251698214,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-10-31,2.2699999809265137,2.2699999809265137,2.0199999809265137,2.259999990463257,29954,0.0,0.0,2.2120000600814818,2.1501250088214876,2.822041658560435,2.1699787105795534,2.8777420385388988,-23.809593586286816,53.497117924711574,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-01,2.259999990463257,2.259999990463257,2.140000104904175,2.25,10560,0.0,0.0,2.2220000505447386,2.15512501001358,2.8033749938011168,1.2601237091960025,3.1030701337708964,-23.123912613223737,53.03507779507717,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-02,2.25,2.2799999713897705,2.25,2.2799999713897705,5450,0.0,0.0,2.2320000410079954,2.159875011444092,2.7837083280086516,2.1505344758012543,3.339314968771307,-22.410153761002107,54.309979215645,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-03,2.180000066757202,2.299999952316284,2.180000066757202,2.299999952316284,884,0.0,0.0,2.2490000247955324,2.161125010251999,2.766291662057241,2.26767127427615,4.0661698942296125,-21.876458657840526,55.183423288745246,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-06,2.299999952316284,4.199999809265137,2.299999952316284,3.190000057220459,44757,0.0,0.0,2.352000021934509,2.1821250140666963,2.757124996185303,35.629252868658504,7.784843066861093,-20.85505673171016,76.61093566903656,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-07,3.0,3.890000104904175,2.799999952316284,3.140000104904175,27175,0.0,0.0,2.450000023841858,2.2031250178813933,2.7474583288033805,28.16326834072124,11.205673938461691,-19.812249933525454,74.45714413880482,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-08,2.8499999046325684,3.069999933242798,2.5199999809265137,2.7899999618530273,18587,0.0,0.0,2.4860000133514406,2.215375018119812,2.735541663567225,12.228477347904619,12.215764510214063,-19.015124221105836,61.43674218566265,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-09,2.9800000190734863,2.9800000190734863,2.4000000953674316,2.4000000953674316,15972,0.0,0.0,2.5070000171661375,2.2206250190734864,2.7207916637261707,-4.268046312965583,12.8961439069139,-18.383129120871295,50.78066574575049,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-10,2.4000000953674316,2.869999885559082,2.2100000381469727,2.5299999713897705,3687,0.0,0.0,2.541000008583069,2.221625018119812,2.7082916617393495,-0.43290189516497724,14.375737933197563,-17.969506404896773,53.66559959570128,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-13,2.5299999713897705,2.9700000286102295,2.180000066757202,2.619999885559082,12422,0.0,0.0,2.5759999990463256,2.227875018119812,2.6947916626930235,1.7080701292331468,15.625875692987012,-17.32663237152075,55.605644235005336,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-14,2.619999885559082,2.619999885559082,2.299999952316284,2.490000009536743,3272,0.0,0.0,2.5990000009536742,2.236625015735626,2.6802916626135507,-4.1939204069617055,16.201865876871757,-16.552924186068072,52.20540722906663,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-15,2.5,2.5,2.25,2.380000114440918,27773,0.0,0.0,2.612000012397766,2.235375016927719,2.663624995946884,-8.882078746388542,16.848403181479462,-16.077712878908006,49.449970963777865,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-16,2.369999885559082,2.369999885559082,2.2300000190734863,2.369999885559082,1342,0.0,0.0,2.6210000038146974,2.2398750126361846,2.6467083275318144,-9.576502017943564,17.015457962091997,-15.371293869582594,49.19575380875613,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-17,2.6600000858306885,2.6600000858306885,2.240000009536743,2.359999895095825,3738,0.0,0.0,2.6269999980926513,2.2458750128746034,2.6301249941190084,-10.163688739652953,16.969999801112156,-14.609571107973673,48.92489495006105,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-20,2.25,2.319999933242798,2.140000104904175,2.319999933242798,5382,0.0,0.0,2.539999985694885,2.2551250100135802,2.614208326737086,-8.661419436658004,12.63233631911117,-13.735834020989984,47.79142482501594,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-21,2.3399999141693115,2.3399999141693115,2.3399999141693115,2.3399999141693115,3220,0.0,0.0,2.4599999666213987,2.2661250084638596,2.5993749936421713,-4.878050978874488,8.555351422954438,-12.820388977866221,48.43469359366827,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-22,2.440000057220459,2.440000057220459,2.180000066757202,2.369999885559082,1493,0.0,0.0,2.4179999589920045,2.2758750051259993,2.5872916599114735,-1.9851147331256498,6.24484884037543,-12.036395417288578,49.44098819960288,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-23,2.200000047683716,2.319999933242798,2.140000104904175,2.309999942779541,16351,0.0,0.0,2.4089999437332152,2.285000002384186,2.577958325544993,-4.109589176671147,5.42669327000643,-11.363966603256639,47.44669861873647,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-24,2.2300000190734863,2.369999885559082,2.130000114440918,2.299999952316284,7864,0.0,0.0,2.3859999418258666,2.2889999985694884,2.568708324432373,-3.604358407644036,4.237655889777122,-10.889065262973903,47.10565684788505,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-27,1.600000023841858,1.600000023841858,1.3350000381469727,1.3550000190734863,124039,0.0,0.0,2.259499955177307,2.273499998450279,2.5533333241939546,-40.03097827159917,-0.6157925349687782,-10.959529768093022,27.205006087549194,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-28,1.3600000143051147,1.3600000143051147,1.2000000476837158,1.2949999570846558,48383,0.0,0.0,2.1399999499320983,2.2558749973773957,2.537958322962125,-39.48598189800211,-5.1365899076859245,-11.114576745905811,26.44120535944154,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-29,1.2949999570846558,1.2949999570846558,1.2350000143051147,1.2599999904632568,2592,0.0,0.0,2.0279999375343323,2.23787499666214,2.522208322087924,-37.86982104175108,-9.378319139399785,-11.273189567085726,25.982936769368393,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-11-30,1.25,1.3049999475479126,1.2100000381469727,1.284999966621399,29897,0.0,0.0,1.919499945640564,2.2192499965429304,2.50458332101504,-33.05548304183064,-13.506817680266153,-11.392446882400852,26.956749796023573,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-01,1.2350000143051147,1.2799999713897705,1.0049999952316284,1.2649999856948853,30343,0.0,0.0,1.80999995470047,2.2001249969005583,2.4867916534344356,-30.11049627875679,-17.73194899152002,-11.527570318887404,26.654621830829555,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-04,1.2649999856948853,1.2649999856948853,1.1050000190734863,1.2000000476837158,24954,0.0,0.0,1.6979999661445617,2.1796249985694884,2.468958321213722,-29.3286176908232,-22.09669244668337,-11.718841916375464,25.648493665872948,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-05,1.2000000476837158,1.2000000476837158,1.149999976158142,1.1549999713897705,18169,0.0,0.0,1.5794999718666076,2.1586249977350236,2.450166653593381,-26.87559405114615,-26.828422096291547,-11.89885004070178,24.946433649569343,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-06,1.149999976158142,1.2450000047683716,1.149999976158142,1.2200000286102295,54325,0.0,0.0,1.4644999861717225,2.137624999880791,2.4311666538318,-16.695115047466018,-31.489387228658277,-12.07410662236394,28.011640752181393,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-07,1.2200000286102295,1.3300000429153442,1.1799999475479126,1.25,18979,0.0,0.0,1.3584999918937684,2.1181250005960464,2.4124166538317997,-7.986749542965975,-35.86308685693797,-12.199039198652132,29.443878041851377,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-08,1.149999976158142,1.184999942779541,1.1299999952316284,1.1549999713897705,64289,0.0,0.0,1.243999993801117,2.090250000357628,2.3932083199421563,-7.154342673218316,-40.48558815508782,-12.659086844218015,27.573085427067298,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-11,1.1549999713897705,1.3849999904632568,1.0049999952316284,1.2799999713897705,61906,0.0,0.0,1.2364999890327453,2.0662499994039534,2.373874987165133,3.5179929432149195,-40.15729028968248,-12.958769498158937,33.55529943589798,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-12,1.2799999713897705,1.375,1.2799999713897705,1.3300000429153442,60261,0.0,0.0,1.2399999976158143,2.0477500021457673,2.35295832157135,7.2580681832722425,-39.44573330160124,-12.971259058331256,35.83818376113547,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-13,1.3300000429153442,1.3300000429153442,1.2599999904632568,1.2999999523162842,22930,0.0,0.0,1.243999993801117,2.0264999985694887,2.3304583211739858,4.501604404679769,-38.61337307282212,-13.04285598428449,35.05984234455396,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-14,1.2999999523162842,1.3200000524520874,1.1799999475479126,1.25,96459,0.0,0.0,1.240499997138977,2.0032499969005584,2.3112916549046836,0.7658204661776169,-38.0756271529621,-13.32768442919977,33.744441546822884,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-15,1.25,1.3949999809265137,1.25,1.3200000524520874,100856,0.0,0.0,1.2460000038146972,1.9829999953508377,2.292708322405815,5.939008700709068,-37.1659098973295,-13.508405060875347,37.291652038004344,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-18,1.3600000143051147,1.409999966621399,1.2400000095367432,1.3250000476837158,52915,0.0,0.0,1.2585000038146972,1.9621249943971635,2.2745833228031795,5.284071805120962,-35.86035510437222,-13.736948005973451,37.548846146634936,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-19,1.3250000476837158,1.3250000476837158,1.2699999809265137,1.2999999523162842,13992,0.0,0.0,1.2730000019073486,1.9406249910593032,2.257749989628792,2.1209701781996273,-34.40257608903238,-14.046063560014844,36.73750761007458,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-20,1.2999999523162842,1.9450000524520874,1.2999999523162842,1.784999966621399,116849,0.0,0.0,1.3294999957084657,1.9244999885559082,2.243791655699412,34.26099829885339,-30.917121142407183,-14.2300051046396,56.4136756907776,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-21,1.784999966621399,1.784999966621399,1.5549999475479126,1.659999966621399,53793,0.0,0.0,1.3704999923706054,1.9112499862909318,2.229958322644234,21.12367572874149,-28.29300184690822,-14.292120759251903,51.93065283568878,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-22,1.5,1.8450000286102295,1.5,1.6200000047683716,51891,0.0,0.0,1.4169999957084656,1.8969999849796295,2.2159583230813342,14.326041614305787,-25.303109808739315,-14.393697515853402,50.54641361659895,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-27,1.6200000047683716,1.9950000047683716,1.3650000095367432,1.6799999475479126,43675,0.0,0.0,1.4569999933242799,1.8822499841451645,2.2033749888340632,15.305419028509244,-22.592641487735996,-14.574232997844142,52.58792710360802,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-28,1.6799999475479126,1.6799999475479126,1.350000023841858,1.4249999523162842,66744,0.0,0.0,1.4664999842643738,1.86137498319149,2.1894999891519547,-2.829869239235407,-21.21415633566046,-14.986298588087921,44.230860405944135,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2023-12-29,1.4850000143051147,1.4850000143051147,1.2649999856948853,1.409999966621399,39003,0.0,0.0,1.4774999856948852,1.8403749823570252,2.1752499898274738,-4.5685292539437965,-19.717448897147843,-15.394782624364408,43.790023093364,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-02,1.409999966621399,1.4700000286102295,1.274999976158142,1.440000057220459,52851,0.0,0.0,1.4964999914169312,1.8193749845027924,2.1623333235581716,-3.7754717354175473,-17.74647864437347,-15.860567624746816,44.971318380784616,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-03,1.440000057220459,1.6799999475479126,1.25,1.5399999618530273,8924,0.0,0.0,1.518499982357025,1.800374984741211,2.150249989827474,1.4158695914259964,-15.656460724747465,-16.271364108427935,48.83151417336912,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-04,1.5800000429153442,1.6950000524520874,1.399999976158142,1.5199999809265137,51995,0.0,0.0,1.537999975681305,1.7586249828338623,2.139583323399226,-1.170350782796186,-12.545312918109488,-17.805258453787292,48.10470160446506,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-05,1.5199999809265137,1.5199999809265137,1.409999966621399,1.4900000095367432,1285,0.0,0.0,1.5569999814033508,1.7173749804496765,2.1288333237171173,-4.303145322212492,-9.338379845520585,-19.327879673970944,46.97525087949357,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-08,1.4900000095367432,1.4900000095367432,1.2599999904632568,1.399999976158142,7051,0.0,0.0,1.518499982357025,1.6826249808073044,2.1176666567722955,-7.803754203206942,-9.754104469050137,-20.543444577253382,43.66316570337777,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-09,1.4700000286102295,1.4800000190734863,1.399999976158142,1.399999976158142,26655,0.0,0.0,1.4924999833106996,1.6576249778270722,2.1079166571299237,-6.197655489909735,-9.961541164324741,-21.361929931136615,43.66316570337777,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-10,1.399999976158142,1.6950000524520874,1.399999976158142,1.5399999618530273,2070,0.0,0.0,1.484499979019165,1.6328749775886535,2.098749989271164,3.7386314326883356,-9.086733559271087,-22.197737418180786,50.02055109116478,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-11,1.4049999713897705,1.5299999713897705,1.350000023841858,1.350000023841858,24284,0.0,0.0,1.4514999866485596,1.6011249810457229,2.088166657090187,-6.992763605948079,-9.34499156333446,-23.323889134555266,42.93872306202442,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-12,1.25,1.4950000047683716,1.215000033378601,1.3600000143051147,38351,0.0,0.0,1.4449999928474426,1.5728749811649323,2.0772499899069468,-5.882351485333318,-8.13001604379138,-24.28090076749061,43.39297630362802,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-15,1.4850000143051147,1.4850000143051147,1.284999966621399,1.399999976158142,3182,0.0,0.0,1.443999993801117,1.5483749777078628,2.065999989708265,-3.0470926476357763,-6.740937137931365,-25.05445375503098,45.26981997515103,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-16,1.309999942779541,1.375,1.25,1.375,8497,0.0,0.0,1.437499988079071,1.5234999805688858,2.0531249890724816,-4.347825293730244,-5.644896198666291,-25.79604316943504,44.281617457896914,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-17,1.350000023841858,1.350000023841858,1.2400000095367432,1.2549999952316284,15234,0.0,0.0,1.408999991416931,1.4958749830722808,2.039499988158544,-10.92973719825476,-5.8076371781365586,-26.65481776134257,39.79153577337718,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-18,1.284999966621399,1.284999966621399,1.2599999904632568,1.2599999904632568,3102,0.0,0.0,1.3829999923706056,1.4693749845027924,2.025833320617676,-8.8937095145253,-5.878349164996463,-27.468120424893577,40.06423870223532,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-19,1.25,1.25,1.2000000476837158,1.2300000190734863,46500,0.0,0.0,1.3569999933242798,1.4416249871253968,2.0131666541099547,-9.358878030623874,-5.870111475374702,-28.390181499268046,38.92504567672656,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-22,1.2000000476837158,1.2000000476837158,1.100000023841858,1.184999942779541,5094,0.0,0.0,1.3354999899864197,1.4119999885559082,1.9997916539510092,-11.269191189466733,-5.417846968095744,-29.392645190502463,37.21564803167247,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-23,1.1050000190734863,1.1799999475479126,0.9959999918937683,1.125,53116,0.0,0.0,1.3079999923706054,1.3823749899864197,1.9850833197434743,-13.990825186393016,-5.380233160652378,-30.361865608489445,35.00812572881394,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-24,1.149999976158142,1.149999976158142,1.0049999952316284,1.100000023841858,45838,0.0,0.0,1.2639999985694885,1.352374991774559,1.971749986211459,-12.97468155959137,-6.534799426385924,-31.412450806046326,34.10048594469214,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-25,1.100000023841858,1.149999976158142,1.0149999856948853,1.1299999952316284,40753,0.0,0.0,1.2419999957084655,1.3467499911785126,1.95933332045873,-9.017713435091416,-7.777983750226909,-31.26488601422835,36.2368742492174,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-26,1.1200000047683716,1.1200000047683716,1.0,1.0800000429153442,22298,0.0,0.0,1.2139999985694885,1.3413749933242798,1.9471666544675827,-11.037887628669068,-9.495852792001331,-31.111443889683173,34.244277487288215,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-29,1.0800000429153442,1.0800000429153442,1.0099999904632568,1.0549999475479126,19073,0.0,0.0,1.1794999957084655,1.3362499922513962,1.9342916548252105,-10.55532417240681,-11.730589145136578,-30.917863967512982,33.25949327357051,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-30,1.0549999475479126,1.100000023841858,1.034999966621399,1.100000023841858,56992,0.0,0.0,1.1519999980926514,1.3316249936819076,1.9217916558186212,-4.513886661188287,-13.489157716437706,-30.709190580043483,36.78352349822219,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-01-31,1.100000023841858,1.100000023841858,1.0,1.100000023841858,14411,0.0,0.0,1.1365000009536743,1.3274999946355819,1.9092083235581716,-3.2116125896337953,-14.387946851505626,-30.468562374506412,36.78352349822219,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-01,1.100000023841858,1.2000000476837158,1.090000033378601,1.1100000143051147,16734,0.0,0.0,1.1215000033378602,1.3252499938011169,1.8972916573286056,-1.0254114131536878,-15.374457001795989,-30.150433715232044,37.63224641494029,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-02,1.0950000286102295,1.1950000524520874,1.0950000286102295,1.0950000286102295,9340,0.0,0.0,1.1080000042915343,1.3237499952316285,1.8859166572491328,-1.1732829991834839,-16.298394086289868,-29.808669426436968,36.83341781572465,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-05,1.090000033378601,1.1549999713897705,1.090000033378601,1.1549999713897705,5406,0.0,0.0,1.1050000071525574,1.322124993801117,1.877458323041598,4.524883612087619,-16.42242508587059,-29.578996371051623,42.12548668867336,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-06,1.1549999713897705,1.1549999713897705,1.0800000429153442,1.100000023841858,24436,0.0,0.0,1.1025000095367432,1.3183749943971634,1.8689583241939545,-0.22675607013697544,-16.374323373687062,-29.459369032974397,38.907614190049635,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-07,1.1399999856948853,1.184999942779541,1.0850000381469727,1.1649999618530273,2469,0.0,0.0,1.1090000033378602,1.318624994158745,1.861333324511846,5.049590473094579,-15.897240818995778,-29.156966310450173,44.32079208421121,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-08,1.190000057220459,1.190000057220459,1.100000023841858,1.1749999523162842,3693,0.0,0.0,1.1134999990463257,1.3159999936819076,1.8538749913374584,5.523121088696101,-15.387537660165709,-29.01355270279074,45.12635661729822,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-09,1.184999942779541,1.184999942779541,1.0149999856948853,1.0750000476837158,20374,0.0,0.0,1.1129999995231628,1.3096249938011169,1.8417499919732412,-3.4141915413950645,-15.013839473791693,-28.8923578385364,39.04309844963092,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-12,1.0950000286102295,1.100000023841858,1.0399999618530273,1.0800000429153442,45202,0.0,0.0,1.115500009059906,1.3041249960660934,1.8311666597922642,-3.1824263430064557,-14.463719932918744,-28.781742006266143,39.48237953907896,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-13,1.0950000286102295,1.0950000286102295,1.0099999904632568,1.0149999856948853,17902,0.0,0.0,1.1070000052452087,1.2982499957084657,1.821958327293396,-8.31075150084979,-14.731368464891869,-28.744254121493736,35.864052497483385,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-14,1.0149999856948853,1.090000033378601,0.8920000195503235,1.0800000429153442,13503,0.0,0.0,1.1050000071525574,1.292249995470047,1.8113749951124192,-2.2624401878181764,-14.490229365361982,-28.659167816885635,41.625267533242685,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-15,1.0800000429153442,1.100000023841858,0.9520000219345093,1.0950000286102295,20960,0.0,0.0,1.1035000085830688,1.2864999949932099,1.800499994556109,-0.7702745724264757,-14.224639496489614,-28.547625721577386,42.89997536829777,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-16,1.0950000286102295,1.0950000286102295,0.9580000042915344,1.0950000286102295,4524,0.0,0.0,1.1035000085830688,1.2813749969005586,1.788541661699613,-0.7702745724264757,-13.881571651369887,-28.356435617893567,42.89997536829776,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-19,1.1649999618530273,1.1649999618530273,0.9200000166893005,1.0149999856948853,53891,0.0,0.0,1.0895000100135803,1.2621249973773956,1.778083328406016,-6.8380012513966335,-13.677328927207489,-29.01766878896263,37.79504978458449,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-20,1.0,1.0,0.949999988079071,0.9879999756813049,12702,0.0,0.0,1.0783000051975251,1.2453249976038934,1.7667333289980889,-8.37429556533099,-13.412160899984979,-29.512565526223767,36.22816487841754,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-21,0.9980000257492065,0.9980000257492065,0.9900000095367432,0.9900000095367432,1112,0.0,0.0,1.0608000099658965,1.2295749977231025,1.7558999960621198,-6.674208122549838,-13.726286568101944,-29.974656843748694,36.43837579551291,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-22,0.9900000095367432,0.9900000095367432,0.9399999976158142,0.9399999976158142,26864,0.0,0.0,1.0373000144958495,1.2110749989748002,1.746483329931895,-9.380122965420496,-14.348821057825054,-30.6563665270125,33.46823770613497,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-23,0.8999999761581421,0.9599999785423279,0.8880000114440918,0.8980000019073486,35982,0.0,0.0,1.019600009918213,1.1979000002145768,1.7364666640758515,-11.92624625617829,-14.884380187363334,-31.015087994672225,31.169885119378577,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-26,0.9559999704360962,1.0850000381469727,0.8980000019073486,0.9039999842643738,12422,0.0,0.0,1.0020000040531158,1.185250000655651,1.7269166643420855,-9.78044105711871,-15.460872938297051,-31.366114814393587,31.889472377033684,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-27,0.9039999842643738,0.9319999814033508,0.8180000185966492,0.9319999814033508,31287,0.0,0.0,0.9937000036239624,1.1725499987602235,1.7172666649023691,-6.209119653375807,-15.253080493400297,-31.719981367780996,35.289425449284224,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-28,0.9100000262260437,0.9380000233650208,0.9100000262260437,0.9380000233650208,11062,0.0,0.0,0.97950000166893,1.1575000002980231,1.7063333317637444,-4.236853316304151,-15.377969640022737,-32.16448517116066,36.02637980467689,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-02-29,0.7919999957084656,0.9399999976158142,0.7919999957084656,0.9399999976158142,3099,0.0,0.0,0.9639999985694885,1.1430000007152556,1.6945833325386048,-2.4896266586399034,-15.660542610127232,-32.549790926896385,36.286844729110435,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-01,0.9399999976158142,1.0399999618530273,0.8299999833106995,1.0199999809265137,29989,0.0,0.0,0.9564999938011169,1.13125,1.6839166661103566,6.638785942177449,-15.447514360122266,-32.82030977144193,45.79391188701502,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-04,1.0199999809265137,1.0199999809265137,0.9020000100135803,0.9739999771118164,22271,0.0,0.0,0.9523999929428101,1.1206000000238419,1.672866666316986,2.267952995491398,-15.009816801486092,-33.013190914313846,41.92047651718385,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-05,0.906000018119812,0.9120000004768372,0.8360000252723694,0.8820000290870667,11584,0.0,0.0,0.9417999982833862,1.107650001347065,1.6619666660825412,-6.349540168328378,-14.973141593642463,-33.353055512362864,35.46028756628601,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-06,0.9459999799728394,0.9459999799728394,0.9440000057220459,0.9440000057220459,7382,0.0,0.0,0.9371999979019165,1.0927500024437904,1.6490833327174186,0.725566350336357,-14.234729278792669,-33.73591371861616,41.95247896230097,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-07,0.9399999976158142,1.440000057220459,0.9380000233650208,1.350000023841858,263989,0.0,0.0,0.9782000005245208,1.0927500024437904,1.640583333869775,38.008589564299136,-10.482727216938336,-33.392593970448694,66.04191686758355,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-08,1.399999976158142,2.240000009536743,1.350000023841858,2.0999999046325684,166121,0.0,0.0,1.0983999907970428,1.1112499997019767,1.6402499988675117,91.18717427416627,-1.1563562572220598,-32.25118119376777,81.39881349404376,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-11,2.119999885559082,2.799999952316284,2.119999885559082,2.630000114440918,177820,0.0,0.0,1.2710000038146974,1.1420000031590463,1.6419166659315427,106.92369052300594,11.295972005149396,-30.447139805896807,86.1614742709028,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-12,2.640000104904175,2.9800000190734863,1.600000023841858,1.8849999904632568,355071,0.0,0.0,1.366300004720688,1.1547500029206277,1.639374998708566,37.96384278346003,18.319982789781488,-29.561570486905463,62.094275150389926,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-13,1.8849999904632568,1.8849999904632568,1.690000057220459,1.8350000381469727,29338,0.0,0.0,1.4560000061988831,1.1692500039935112,1.6369999999801317,26.030221863633685,24.524267797818478,-28.57361001785569,60.86547467255161,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-14,1.8350000381469727,1.850000023841858,1.659999966621399,1.7400000095367432,46166,0.0,0.0,1.5360000073909759,1.1812500044703484,1.6352499996622403,13.281250075791231,30.031746165342117,-27.763338650705716,58.496824469019195,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-15,1.7400000095367432,1.809999942779541,1.5499999523162842,1.7000000476837158,25804,0.0,0.0,1.6040000140666961,1.193000005185604,1.6335833335916201,5.985039449820598,34.4509645510982,-26.97036137344418,57.48247891557319,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-18,1.7999999523162842,1.875,1.649999976158142,1.75,21806,0.0,0.0,1.6816000163555145,1.2071250066161157,1.6316666667660078,4.067553697622276,39.3062033458718,-26.01889643252572,58.45230807557845,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-19,1.75,1.8650000095367432,1.6349999904632568,1.784999966621399,16859,0.0,0.0,1.7719000101089477,1.2236250057816505,1.6303333327174188,0.739316916175521,44.80743706092045,-24.946329610882216,59.15465644568172,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-20,1.784999966621399,1.9950000047683716,1.149999976158142,1.6100000143051147,17764,0.0,0.0,1.8385000109672547,1.2363750055432319,1.6259166652957597,-12.428610024425488,48.700839367054684,-23.958279539601676,54.2193412266015,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-21,1.8450000286102295,1.8450000286102295,1.5,1.6449999809265137,26220,0.0,0.0,1.8680000066757203,1.2492500051856041,1.623166664938132,-11.937902834703728,49.529717744382715,-23.036245619717672,55.027482965979864,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-22,1.6449999809265137,1.6449999809265137,1.5,1.625,6587,0.0,0.0,1.8205000162124634,1.2628750041127206,1.620041664938132,-10.738808814690357,44.1552022396328,-22.04675771959552,54.43613997032865,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-25,1.625,1.684999942779541,1.559999942779541,1.6549999713897705,17596,0.0,0.0,1.7230000019073486,1.277875004708767,1.6173333312074343,-3.946606525960681,34.83321886400207,-20.98876712354909,55.213606748971515,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-26,1.6649999618530273,1.690000057220459,1.5700000524520874,1.690000057220459,12247,0.0,0.0,1.703500008583069,1.292625005543232,1.6144999985893567,-0.7924831989780201,31.78609428704071,-19.936512438981588,56.15360739480059,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-27,1.690000057220459,1.690000057220459,1.5499999523162842,1.6649999618530273,11319,0.0,0.0,1.6865000009536744,1.3067500039935112,1.6114583318432172,-1.274831846337935,29.060646320996597,-18.90885552722761,55.2614093667535,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-03-28,1.6799999475479126,1.6799999475479126,1.5299999713897705,1.6449999809265137,7225,0.0,0.0,1.6769999980926513,1.3201250031590461,1.6083333318432171,-1.908170375821891,27.03342441659743,-17.919688846706435,54.51517777676633,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-02,1.6449999809265137,1.6449999809265137,1.5199999809265137,1.6349999904632568,1325,0.0,0.0,1.6704999923706054,1.333625002205372,1.605333331724008,-2.125112365727734,25.260098574048502,-16.925352769374168,54.121648203305355,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-03,1.6100000143051147,1.6100000143051147,1.3550000190734863,1.5399999618530273,14600,0.0,0.0,1.6494999885559083,1.3432500019669533,1.6009999985496204,-6.638376930135367,22.799180058850233,-16.099312730553915,50.399489285637614,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-04,1.3650000095367432,1.524999976158142,1.3650000095367432,1.5049999952316284,35670,0.0,0.0,1.6214999914169312,1.3533750012516976,1.5966249987483025,-7.184705322354056,19.81158141071414,-15.23526173568022,49.06077805644517,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-05,1.5199999809265137,1.5199999809265137,1.0299999713897705,1.4500000476837158,58230,0.0,0.0,1.6054999947547912,1.3605000033974648,1.5897916659712792,-9.685452979078022,18.008084582543777,-14.422749060879573,46.95031102233552,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-08,1.4500000476837158,1.4900000095367432,1.2799999713897705,1.4500000476837158,32088,0.0,0.0,1.5860000014305116,1.3673750057816505,1.5832083329558373,-8.57502860177358,15.988664025922105,-13.632654823842906,46.95031102233552,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-09,1.4500000476837158,1.4500000476837158,1.3250000476837158,1.4149999618530273,16670,0.0,0.0,1.5649999976158142,1.3758750036358833,1.5777499998609226,-9.584666836504992,13.745797654594327,-12.795119394253485,45.50558645524618,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-10,1.409999966621399,2.4200000762939453,1.409999966621399,2.1700000762939453,154801,0.0,0.0,1.6165000081062317,1.4031250044703483,1.5779166663686435,34.24064741182106,15.207127159452789,-11.077369649726434,68.22187708228306,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-11,2.180000066757202,2.390000104904175,1.625,1.850000023841858,70957,0.0,0.0,1.6325000047683715,1.4240000054240227,1.5751666660110155,13.32312517232406,14.64185383077046,-9.596867674314767,57.31624422064606,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-12,1.7300000190734863,1.8450000286102295,1.649999976158142,1.774999976158142,65048,0.0,0.0,1.6435000061988831,1.4413750037550925,1.5722083315253257,8.00121505708993,14.02306838381486,-8.321627938665179,55.09333147167938,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-15,1.75,1.75,1.4700000286102295,1.5099999904632568,37760,0.0,0.0,1.6300000071525573,1.4517500028014183,1.5667916640639306,-7.361964181762685,12.278285104678691,-7.342498935954139,48.00846731386088,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-16,1.7100000381469727,1.7100000381469727,1.5099999904632568,1.6549999713897705,18341,0.0,0.0,1.6320000052452088,1.4657500013709068,1.562583329776923,1.409311646485315,11.342316474078759,-6.1970025252886956,51.67073011053398,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-17,1.7300000190734863,1.7300000190734863,1.4950000047683716,1.684999942779541,28886,0.0,0.0,1.64650000333786,1.4825000002980233,1.5563749954104424,2.338289666786038,11.062394806534114,-4.746606398218126,52.41752526137437,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-18,1.6399999856948853,1.6399999856948853,1.524999976158142,1.5950000286102295,17203,0.0,0.0,1.6555000066757202,1.4976750016212463,1.5514166618386904,-3.6544837101496572,10.538000893626915,-3.4640378396962137,49.92513283912211,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-19,1.590000033378601,1.590000033378601,1.5449999570846558,1.559999942779541,19113,0.0,0.0,1.6664999961853026,1.5119249999523163,1.5461666608850162,-6.390642283201038,10.22372116592168,-2.2146164316529857,48.95035102774654,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-22,1.4299999475479126,1.5,1.4299999475479126,1.5,17087,0.0,0.0,1.671499991416931,1.5259250000119209,1.5397499943772952,-10.26024482785372,9.540114448866944,-0.8978726686708264,47.247285114710266,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-23,1.5,1.5,1.399999976158142,1.4500000476837158,26345,0.0,0.0,1.675,1.5397250011563302,1.5329999948541324,-13.432832974106521,8.785659695210422,0.4386827348187722,45.816734539769264,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-24,1.4500000476837158,1.600000023841858,1.4249999523162842,1.5800000429153442,4356,0.0,0.0,1.61599999666214,1.5566250026226043,1.5274166618784268,-2.227719914675361,3.8143415363045383,1.9122706641327873,50.05130113233678,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-25,1.5800000429153442,2.0,1.5750000476837158,1.9600000381469727,22475,0.0,0.0,1.6269999980926513,1.582325004041195,1.5247499957680701,20.4671198798218,2.823376609568718,3.7760294102589733,59.913374495025586,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-26,1.9600000381469727,1.9600000381469727,1.7450000047683716,1.840000033378601,12613,0.0,0.0,1.6335000038146972,1.6048750042915345,1.5209166631102562,12.641568967350251,1.7836279739305338,5.520245994911025,56.14350816819052,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-29,1.850000023841858,2.049999952316284,1.8450000286102295,1.9800000190734863,42475,0.0,0.0,1.6805000066757203,1.6308750048279763,1.5108333294590315,17.822077429813387,3.042845202779866,7.945394970332494,59.356603255732146,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-04-30,1.9800000190734863,2.049999952316284,1.7000000476837158,1.9950000047683716,8846,0.0,0.0,1.7145000100135803,1.6552500054240227,1.5012916619578998,16.360454541646195,3.5795199755567846,10.255058851478543,59.69730263309968,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-02,1.9950000047683716,1.9950000047683716,1.784999966621399,1.784999966621399,12167,0.0,0.0,1.724500012397766,1.6755250051617623,1.4929166619976362,3.508260585020987,2.9229648668403807,12.231650152513017,52.99903470691376,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-03,1.9950000047683716,1.9950000047683716,1.6449999809265137,1.9500000476837158,15606,0.0,0.0,1.7600000143051147,1.7022250056266786,1.489166661600272,10.795456354221521,3.3940876492509333,14.307219569195315,57.07446089794963,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-06,1.9500000476837158,1.9500000476837158,1.7000000476837158,1.899999976158142,135611,0.0,0.0,1.794000017642975,1.726125004887581,1.4839166616400083,5.908581798925172,3.932218846445281,16.32223355318934,55.503878457618384,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-07,1.9900000095367432,2.180000066757202,1.9500000476837158,2.140000104904175,17554,0.0,0.0,1.8580000281333924,1.7458750069141389,1.479916663467884,15.17761423578066,6.422282281103056,17.971170270022878,61.0451115265705,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-08,2.1500000953674316,2.5,1.8849999904632568,2.390000104904175,3671,0.0,0.0,1.9520000338554382,1.753125011920929,1.4790833309292792,22.438527840782516,11.344029694528086,18.527805381964157,65.82006080495468,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-10,2.390000104904175,2.5,2.009999990463257,2.2100000381469727,17525,0.0,0.0,2.015000033378601,1.7426250100135803,1.4776666636268299,9.677419431175412,15.630156906958314,17.93086038338502,60.107236119090544,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-13,2.200000047683716,2.200000047683716,2.059999942779541,2.200000047683716,53059,0.0,0.0,2.0390000343322754,1.7505000114440918,1.4762499983112016,7.896027986294967,16.48100662679703,18.57747762551237,59.79672182555445,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-14,2.2899999618530273,2.2899999618530273,2.0199999809265137,2.180000066757202,11868,0.0,0.0,2.0730000376701354,1.7591250121593476,1.4747499997417133,5.1616028529997084,17.84267879435711,19.282930155445975,59.1386985139506,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-15,2.1500000953674316,2.1500000953674316,2.0,2.109999895095825,6861,0.0,0.0,2.0860000252723694,1.7683750092983246,1.4729999994238219,1.1505210705988433,17.961406053802783,20.0526143917204,56.78343360927323,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-16,2.109999895095825,2.109999895095825,2.0,2.059999942779541,21664,0.0,0.0,2.092500019073486,1.7773750066757201,1.470666666328907,-1.553169701204374,17.729798788335284,20.855054878779676,55.09556058261839,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-17,1.9149999618530273,2.0799999237060547,1.7000000476837158,1.815000057220459,133989,0.0,0.0,2.0955000281333924,1.7790000081062316,1.4660416677594186,-13.385825203867654,17.790894805227076,21.34716544756287,47.625284083497526,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-20,1.815000057220459,1.815000057220459,1.600000023841858,1.6950000524520874,116682,0.0,0.0,2.0700000286102296,1.7767500102519989,1.4609166686733563,-18.115940626817874,16.504855306945444,21.618847149266056,44.4465227233373,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-21,1.6950000524520874,1.6950000524520874,1.5099999904632568,1.6699999570846558,11930,0.0,0.0,2.047000026702881,1.7782500088214874,1.4556666687130928,-18.41719905717159,15.113173993993351,22.16052253182248,43.79075823216773,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-22,1.6699999570846558,1.6699999570846558,1.5549999475479126,1.6299999952316284,26671,0.0,0.0,1.9960000157356261,1.7778750091791153,1.4579583351810774,-18.33667422938914,12.268860602142329,21.9427857626881,42.70510166897425,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-23,1.6799999475479126,1.6799999475479126,1.5299999713897705,1.600000023841858,6302,0.0,0.0,1.9170000076293945,1.7772500097751618,1.460500002404054,-16.536253652891002,7.863271744863422,21.687778627163432,41.86675196858294,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-24,1.5499999523162842,1.5700000524520874,1.5,1.5499999523162842,10272,0.0,0.0,1.8509999990463257,1.7746250092983247,1.4629166687528292,-16.26148281389104,4.303725539075956,21.30732031450801,40.44176775670502,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-27,1.5499999523162842,1.6349999904632568,1.465000033378601,1.534999966621399,27347,0.0,0.0,1.784499990940094,1.7707500070333482,1.4650000020861627,-13.981508858806762,0.7765062178247342,20.870307475207984,40.0018958152333,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-28,1.4800000190734863,1.5750000476837158,1.4800000190734863,1.5750000476837158,18683,0.0,0.0,1.7239999890327453,1.7685000091791152,1.4675833359360695,-8.642688068265377,-2.5162578408481586,20.504230722346808,41.819211772185945,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-29,1.5750000476837158,1.6050000190734863,1.5049999952316284,1.6050000190734863,15768,0.0,0.0,1.6735000014305115,1.7675000101327896,1.470958335697651,-4.0932167492364036,-5.318246572186215,20.15976028950499,43.208589147313454,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-30,1.600000023841858,1.600000023841858,1.2599999904632568,1.559999942779541,10908,0.0,0.0,1.6235000014305114,1.7656250089406966,1.4743333354592323,-3.911306350170541,-8.049557906718508,19.757517955783822,41.60368352409525,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-05-31,1.559999942779541,1.6549999713897705,1.4049999713897705,1.6549999713897705,7301,0.0,0.0,1.6074999928474427,1.7685000091791152,1.4779583349823953,2.954897589653408,-9.103761125022775,19.65831291178995,46.15097146261714,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-03,1.6399999856948853,1.6399999856948853,1.6399999856948853,1.6399999856948853,4150,0.0,0.0,1.6019999861717225,1.7718750089406967,1.481208334863186,2.37203494701463,-9.58730282394653,19.62361858464418,45.54787481830237,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-04,1.524999976158142,1.625,1.524999976158142,1.625,3352,0.0,0.0,1.5974999904632567,1.7762500077486039,1.4851250017682711,1.7214403568646386,-10.06333660833661,19.602727422520218,44.91576928716631,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-05,1.659999966621399,1.8700000047683716,1.6299999952316284,1.8200000524520874,34674,0.0,0.0,1.6164999961853028,1.7855000078678132,1.4896250024437905,12.588930203960047,-9.465136428888886,19.862381803381904,53.87699875171747,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-07,1.8300000429153442,1.8300000429153442,1.6549999713897705,1.815000057220459,13621,0.0,0.0,1.6379999995231629,1.795500010251999,1.4936666692296663,10.805864331429943,-8.771930372015472,20.207543439259986,53.63605443999122,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-10,1.6050000190734863,1.7350000143051147,1.6050000190734863,1.6950000524520874,8921,0.0,0.0,1.6525000095367433,1.7836250096559525,1.4969583367307981,2.57186339909665,-7.351601340491533,19.149943314468235,48.07876584957957,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-11,1.6449999809265137,1.6549999713897705,1.375,1.600000023841858,36323,0.0,0.0,1.6590000152587892,1.7773750096559524,1.499875003596147,-3.556358702487882,-6.660102328099976,18.50154215481042,44.17643613851548,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-12,1.6649999618530273,1.6649999618530273,1.4550000429153442,1.6150000095367432,19310,0.0,0.0,1.6630000114440917,1.7733750104904176,1.5023333365718523,-2.8863500647644016,-6.224007803955816,18.041380519256162,44.93638982063923,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-13,1.7599999904632568,1.7599999904632568,1.565000057220459,1.7200000286102295,12512,0.0,0.0,1.674500012397766,1.7786250114440918,1.5056250030795733,2.717229971668418,-5.854241246826118,18.132005499784484,50.06134019125126,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-14,1.7450000047683716,1.7450000047683716,1.6050000190734863,1.7050000429153442,7240,0.0,0.0,1.6890000224113464,1.7798750132322312,1.5090000038345655,0.9473072996858216,-5.105695071018325,17.950630133156864,49.3546337240826,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-17,1.7050000429153442,1.7050000429153442,1.6100000143051147,1.659999966621399,4687,0.0,0.0,1.6895000219345093,1.7792500138282776,1.5079583371678988,-1.7460819727798689,-5.0442597272015774,17.99066127847355,47.20183908964496,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-18,1.659999966621399,1.6649999618530273,1.409999966621399,1.600000023841858,27901,0.0,0.0,1.6855000257492065,1.7793750137090683,1.507458337644736,-5.072678766014482,-5.275728120076349,18.03808896564113,44.41973784996021,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-19,1.4049999713897705,1.600000023841858,1.4049999713897705,1.590000033378601,3031,0.0,0.0,1.6820000290870667,1.7801250159740447,1.5072083378831544,-5.469678603893969,-5.512252566895489,18.10742889560952,43.954737654971765,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-20,1.5750000476837158,1.5750000476837158,1.5099999904632568,1.5700000524520874,4847,0.0,0.0,1.6570000290870666,1.781875017285347,1.5062916720906894,-5.2504511229799,-7.008066614488212,18.295483557454443,42.98553595136405,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-24,1.5700000524520874,1.5700000524520874,1.3650000095367432,1.559999942779541,1400,0.0,0.0,1.6315000176429748,1.7846250146627427,1.5074166720112165,-4.3824746607560465,-8.580233705213718,18.38962960928851,42.48114813525127,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-25,1.5549999475479126,1.5549999475479126,1.5,1.5449999570846558,10999,0.0,0.0,1.6165000081062317,1.7837500125169754,1.5085416719317437,-4.423139539933562,-9.376314126817812,18.243336972774323,41.69091643347684,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-26,1.5449999570846558,1.5449999570846558,1.4149999618530273,1.5199999809265137,8248,0.0,0.0,1.6085000038146973,1.772750011086464,1.5092083379626273,-5.502021925912223,-9.265266182178895,17.462246032884217,40.34391014477095,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-27,1.5,1.5299999713897705,1.4950000047683716,1.5299999713897705,15513,0.0,0.0,1.6,1.765000009536743,1.509125004708767,-4.375001788139349,-9.348442416158983,16.955189532318112,41.162798814070015,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-06-28,1.440000057220459,1.5199999809265137,1.440000057220459,1.5,10368,0.0,0.0,1.577999997138977,1.753000009059906,1.508958338201046,-4.9429656071227175,-9.982887108755776,16.172856776801552,39.4148223169429,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-01,1.5,1.5149999856948853,1.4249999523162842,1.5149999856948853,15594,0.0,0.0,1.5589999914169312,1.7410000085830688,1.5091666713356973,-2.8223223838542566,-10.45376314008523,15.361678842416126,40.769179236450285,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-02,1.4149999618530273,1.7200000286102295,1.4149999618530273,1.684999942779541,19388,0.0,0.0,1.5614999890327455,1.7385000079870223,1.5115416710575422,7.90905889300046,-10.181191725113765,15.015023487290952,53.4656506956202,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-03,1.5850000381469727,1.5950000286102295,1.5850000381469727,1.5950000286102295,1392,0.0,0.0,1.5609999895095825,1.7296250075101853,1.5131666714946428,2.1780934868121764,-9.749224095883097,14.30498966790843,47.643100114484284,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-04,1.5950000286102295,1.5950000286102295,1.5,1.565000057220459,4233,0.0,0.0,1.5584999918937683,1.7212500095367431,1.5133750056227049,0.41707188710295073,-9.455338663253068,13.735855497924282,45.850648963140756,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-05,1.4800000190734863,1.5549999475479126,1.4800000190734863,1.5449999570846558,3010,0.0,0.0,1.5559999823570252,1.7063750058412552,1.5150000050663948,-0.7069425062400462,-8.81254255186972,12.63201321022263,44.64474242332239,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-08,1.4900000095367432,1.559999942779541,1.4900000095367432,1.559999942779541,11279,0.0,0.0,1.5559999823570252,1.6856250017881393,1.516666671137015,0.25706686811504287,-7.690027099361113,11.140109680425674,45.796182641922975,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-09,1.559999942779541,1.559999942779541,1.475000023841858,1.5499999523162842,10370,0.0,0.0,1.556499981880188,1.669124999642372,1.517916670938333,-0.41760550206058794,-6.747548433239888,9.961569801494203,45.122326139557074,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-10,1.3722219467163086,1.4685180187225342,1.3722219467163086,1.4011110067367554,8057,0.0,0.0,1.5446110844612122,1.6491527736186982,1.5181342626611392,-9.290369541437817,-6.339114897650902,8.630232132953546,36.5087634283948,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-11,1.4011110067367554,1.4011110067367554,1.3722219467163086,1.3962960243225098,27341,0.0,0.0,1.5312406897544861,1.6295601725578308,1.5193117295702299,-8.81276642757011,-6.033498146252433,7.256472838446861,36.267646529997776,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-12,1.367406964302063,1.4685180187225342,1.3577769994735718,1.444443941116333,4763,0.0,0.0,1.5256850838661193,1.6129212737083436,1.5208487624923388,-5.3248959178338096,-5.408583249798387,6.054021510009849,40.49939081775098,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-15,0.9610369801521301,0.9610369801521301,0.7357029914855957,0.8647400140762329,245419,0.0,0.0,1.4606590867042542,1.5830397754907608,1.5178049291173616,-40.79795744622506,-7.730739977684213,4.297973021561783,21.76286761699511,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-16,0.8666660189628601,0.8685920238494873,0.7260739803314209,0.7684440016746521,151458,0.0,0.0,1.3690034925937653,1.5568758741021156,1.5143336296081542,-43.8683680624708,-12.067267829986793,2.809304611756494,20.099414145289344,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-17,0.7703700065612793,0.8069620132446289,0.7318509817123413,0.7877029776573181,4580,0.0,0.0,1.2882737874984742,1.5341934472322465,1.511522821088632,-38.85593378509605,-16.02924717071516,1.4998533814584813,21.39349847095444,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-18,0.7318509817123413,0.7318509817123413,0.7260739803314209,0.7279989719390869,12639,0.0,0.0,1.204573678970337,1.5106434226036072,1.5084228123227754,-39.5637656169462,-20.26088612663843,0.147214047857862,20.29606207866904,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-19,0.7599999904632568,0.7599999904632568,0.7020000219345093,0.7020000219345093,15913,0.0,0.0,1.1202736854553224,1.4874434232711793,1.504856145878633,-37.33673913359936,-24.68461872710283,-1.1571021359843638,19.819277298450075,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-22,0.699999988079071,0.8180000185966492,0.699999988079071,0.8140000104904175,15564,0.0,0.0,1.0456736922264098,1.4677934229373932,1.5026394789417585,-22.155447101544777,-28.75879698835443,-2.3189897838239824,27.69884986784848,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-23,0.8140000104904175,0.8180000185966492,0.7860000133514404,0.7860000133514404,21676,0.0,0.0,0.9692736983299255,1.448693424463272,1.5003978128234545,-18.908352232632396,-33.093249271216045,-3.4460453033375797,26.98488321428958,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-24,0.7540000081062317,0.7540000081062317,0.722000002861023,0.7480000257492065,79526,0.0,0.0,0.9039626002311707,1.4290184259414673,1.4974644795060157,-17.25321096714397,-36.742411166908425,-4.570796469718426,26.005198099300827,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-25,0.7179999947547913,0.7480000257492065,0.7039999961853027,0.7400000095367432,3704,0.0,0.0,0.838332998752594,1.4081434249877929,1.4944644793868065,-11.729585899894962,-40.46536852168581,-5.776052598749754,25.792894118431818,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-26,0.7020000219345093,0.7020000219345093,0.699999988079071,0.699999988079071,16379,0.0,0.0,0.7638886034488678,1.3855184242129326,1.4910478125015894,-8.36360368270283,-44.8662255153476,-7.077532149127127,24.70679748581115,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-29,0.699999988079071,0.7120000123977661,0.699999988079071,0.7120000123977661,20998,0.0,0.0,0.7486146032810211,1.3643184259533883,1.487856145699819,-4.890980048048881,-45.12904106254463,-8.303068821772701,25.717357986136733,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-30,0.7120000123977661,0.8360000252723694,0.7120000123977661,0.7120000123977661,97848,0.0,0.0,0.7429702043533325,1.340743426978588,1.4841644793748856,-4.16842987432077,-44.585206281589485,-9.66342035464324,25.717357986136733,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-07-31,0.7080000042915344,0.7080000042915344,0.6740000247955322,0.6779999732971191,8134,0.0,0.0,0.7319999039173126,1.3166934266686439,1.4806478122870128,-7.377040670526284,-44.40620047983834,-11.073152187698474,24.631042430165508,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-01,0.6779999732971191,0.75,0.6779999732971191,0.699999988079071,24182,0.0,0.0,0.729200005531311,1.2935684263706206,1.476772812505563,-4.004390733782869,-43.628803033076835,-12.405725822112686,26.786064104662458,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-02,0.7400000095367432,0.7400000095367432,0.7099999785423279,0.7099999785423279,8459,0.0,0.0,0.7300000011920929,1.2658184245228767,1.4728978127241135,-2.7397291256308023,-42.32980125350515,-14.059318060785559,27.79666043206612,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-05,0.6899999976158142,0.7099999785423279,0.6899999976158142,0.699999988079071,1321,0.0,0.0,0.7185999989509583,1.237943422794342,1.469772812227408,-2.588367784447577,-41.95211301911505,-15.773144495830877,27.389511840935796,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-06,0.7099999785423279,0.7099999785423279,0.7099999785423279,0.7099999785423279,2000,0.0,0.0,0.710999995470047,1.2133184209465981,1.466689478357633,-0.14064935781863094,-41.40037905998789,-17.27503068302871,28.51709144875167,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-07,0.7099999785423279,0.7099999785423279,0.7059999704360962,0.7059999704360962,12286,0.0,0.0,0.7067999899387359,1.190968419611454,1.4641144782304765,-0.11318895218279394,-40.65333905584793,-18.656058845148895,28.327593936033637,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-08,0.6899999976158142,0.7039999961853027,0.6899999976158142,0.7039999961853027,24339,0.0,0.0,0.7031999886035919,1.168193419277668,1.460981144507726,0.11376672279240013,-39.80448982169379,-20.040486239725716,28.226597735531257,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-09,0.699999988079071,0.699999988079071,0.6779999732971191,0.6779999732971191,12873,0.0,0.0,0.7009999871253967,1.1421434178948402,1.4575061440467834,-3.2810291370466516,-38.624171348160814,-21.63714557499804,26.884655468138575,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-12,0.6700000166893005,0.671999990940094,0.6700000166893005,0.671999990940094,35399,0.0,0.0,0.6969999849796296,1.116318416595459,1.4539811437328656,-3.586799796023843,-37.56261881754707,-23.22332229636151,26.57072059816265,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-13,0.699999988079071,0.699999988079071,0.671999990940094,0.699999988079071,15084,0.0,0.0,0.69579998254776,1.0923184171319007,1.4513561437527338,0.6036225404795504,-36.30062703009977,-24.738085697730856,30.64105647784541,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-14,0.699999988079071,0.699999988079071,0.6700000166893005,0.6700000166893005,10522,0.0,0.0,0.6949999868869782,1.0690684169530869,1.448706144094467,-3.5971180819235267,-34.9901301108705,-26.20529557971039,28.799067828886578,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-15,0.6700000166893005,0.699999988079071,0.6700000166893005,0.699999988079071,14291,0.0,0.0,0.6949999868869782,1.0468184158205986,1.4462894772489865,0.7194246455296668,-33.60835304543537,-27.62040848061959,33.128294236845505,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-16,0.699999988079071,0.7099999785423279,0.699999988079071,0.7099999785423279,3651,0.0,0.0,0.6949999868869782,1.0253184139728546,1.4443728104233742,2.158272221347398,-32.21618012359443,-29.012897046136338,34.55670529484112,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-19,0.7099999785423279,0.7099999785423279,0.6700000166893005,0.6700000166893005,4902,0.0,0.0,0.6919999897480011,1.0030684158205987,1.4424728105465572,-3.17918690529347,-31.011685859744283,-30.461884030900165,31.64491919780069,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-20,0.6299999952316284,0.6299999952316284,0.550000011920929,0.550000011920929,49818,0.0,0.0,0.6759999930858612,0.9781934171915054,1.4395228107770284,-18.639050658825752,-30.893013466935077,-32.047383350355226,24.87361387838844,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-21,0.6200000047683716,0.6200000047683716,0.6200000047683716,0.6200000047683716,25168,0.0,0.0,0.6673999965190888,0.9556934177875519,1.436922810971737,-7.102186394656576,-30.165889594161673,-33.49027446079359,33.77561699620141,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-22,0.6200000047683716,0.6600000262260437,0.6200000047683716,0.6600000262260437,6090,0.0,0.0,0.6629999995231628,0.9339434191584587,1.4346061443289122,-0.45248466052439085,-29.010688878715246,-34.898967019596604,38.27645147736625,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-23,0.6800000071525574,0.6800000071525574,0.5619999766349792,0.6740000247955322,9113,0.0,0.0,0.6626000046730042,0.913293419778347,1.4323894778887432,1.7204980443901463,-27.449383700386804,-36.239868145046195,39.81812801877591,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-26,0.6600000262260437,0.7400000095367432,0.6600000262260437,0.7300000190734863,6732,0.0,0.0,0.6684000074863434,0.893668420612812,1.429972811539968,9.216039930759798,-25.207158262568583,-37.50451663130562,45.664308897369565,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-27,0.7300000190734863,0.7300000190734863,0.6200000047683716,0.6299999952316284,74648,0.0,0.0,0.6614000082015992,0.8672934219241142,1.4271061450242997,-4.7475071939218685,-23.73976425022743,-39.227125820459094,38.47646656373199,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-28,0.6299999952316284,0.6299999952316284,0.5519999861717224,0.5519999861717224,89846,0.0,0.0,0.6496000051498413,0.8412184208631516,1.4243561446666717,-15.02463334426941,-22.7786756638895,-40.9404435812636,33.98317282883316,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-29,0.8180000185966492,0.8180000185966492,0.5619999766349792,0.5619999766349792,14110,0.0,0.0,0.6358000040054321,0.8161434188485146,1.4211728110909463,-11.6074279499096,-22.097024944160733,-42.57254202449793,35.0307050674044,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-08-30,0.5619999766349792,0.6959999799728394,0.5619999766349792,0.6899999976158142,22611,0.0,0.0,0.6338000059127807,0.7947684198617935,1.415672810872396,8.86714912886374,-20.253498997482108,-43.85931454231826,46.69097551157965,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-02,0.6899999976158142,0.6899999976158142,0.6880000233650208,0.6899999976158142,3766,0.0,0.0,0.6358000040054321,0.7730184212327004,1.4039228116472562,8.524692241102755,-17.750989298347086,-44.93868075797562,46.69097551157965,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-03,0.6899999976158142,0.6899999976158142,0.5799999833106995,0.6579999923706055,6198,0.0,0.0,0.6466000020503998,0.7507184222340584,1.3874894772966704,1.7630668549421198,-13.869170796929852,-45.89375742894076,44.38150778466137,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-04,0.6539999842643738,0.6539999842643738,0.6539999842643738,0.6539999842643738,500,0.0,0.0,0.65,0.7320406466722489,1.3772311439116796,0.6153821945190395,-11.20711630497484,-46.84692907879856,44.0879494902568,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-05,0.6000000238418579,0.6000000238418579,0.6000000238418579,0.6000000238418579,41174,0.0,0.0,0.6439999997615814,0.7121332466602326,1.3669394771258037,-6.83229440000201,-9.5674857504804,-47.90308871921673,40.22023700760565,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-06,0.6000000238418579,0.7179999947547913,0.5820000171661377,0.7160000205039978,1956,0.0,0.0,0.648199999332428,0.6939221486449242,1.3584061438838642,10.459737926781253,-6.588945085811339,-48.916445072833056,50.305588757923864,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-09,0.7160000205039978,0.7160000205039978,0.550000011920929,0.6899999976158142,15048,0.0,0.0,0.6441999971866608,0.6895536482334137,1.349989476799965,7.109593391675011,-6.577247638808914,-48.92155382811266,48.33716554432864,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-10,0.7160000205039978,0.7160000205039978,0.6100000143051147,0.6100000143051147,14105,0.0,0.0,0.6421999990940094,0.6855925485491753,1.3404894769191742,-5.014011964235614,-6.329203773727057,-48.85505926351158,42.789160387031245,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-11,0.5979999899864197,0.6000000238418579,0.5979999899864197,0.6000000238418579,32717,0.0,0.0,0.647000002861023,0.6808999747037887,1.3306144773960114,-7.264293479340337,-4.978700705270725,-48.82815524175735,42.13809449892085,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-12,0.6000000238418579,0.7059999704360962,0.6000000238418579,0.6000000238418579,21118,0.0,0.0,0.6508000075817109,0.6777000010013581,1.3221978108088175,-7.805774915187717,-3.9693069765235713,-48.74443177403281,42.13809449892086,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-13,0.5759999752044678,0.6499999761581421,0.5759999752044678,0.6499999761581421,14498,0.0,0.0,0.6468000054359436,0.6763999998569489,1.3139061441024145,0.494738821166472,-4.376107987472697,-48.51991499598119,46.82948331739,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-16,0.5519999861717224,0.6480000019073486,0.5519999861717224,0.6480000019073486,11302,0.0,0.0,0.642600005865097,0.6722499996423721,1.3057644774516424,0.8403355108878177,-4.4105606237335016,-48.51674928740982,46.666496158897246,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-17,0.6480000019073486,0.6480000019073486,0.5400000214576721,0.5460000038146973,17058,0.0,0.0,0.6314000070095063,0.6662499994039536,1.2965228110551834,-13.52549924718693,-5.230768093902456,-48.612550915188166,39.177390317173845,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-18,0.5460000038146973,0.6179999709129333,0.5460000038146973,0.6179999709129333,10804,0.0,0.0,0.6278000056743622,0.6629999980330468,1.2875894770026206,-1.561012212942241,-5.309199466533033,-48.50843301574316,45.7906529228176,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-19,0.6179999709129333,0.6179999709129333,0.5239999890327454,0.5799999833106995,9429,0.0,0.0,0.6258000016212464,0.6589999973773957,1.278547810514768,-7.318635057828988,-5.0379356431372395,-48.45714865273052,43.125508273150494,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-20,0.5699999928474426,0.5699999928474426,0.5680000185966492,0.5680000185966492,7181,0.0,0.0,0.6110000014305115,0.6556999981403351,1.2695728108286857,-7.037640381863838,-6.817141503217873,-48.35270631604489,42.2884665928474,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-23,0.6159999966621399,0.6159999966621399,0.6039999723434448,0.6039999723434448,5380,0.0,0.0,0.6023999989032746,0.652999997138977,1.2609811440110206,0.2655998411492641,-7.748851218590951,-48.21492769813614,45.6938685487038,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-24,0.6159999966621399,0.6159999966621399,0.6039999723434448,0.6159999966621399,4599,0.0,0.0,0.602999997138977,0.6505999967455864,1.2532811443010965,2.1558871616655577,-7.316323369922049,-48.08826417727689,46.820329842210235,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-25,0.6200000047683716,0.6200000047683716,0.6000000238418579,0.6200000047683716,7114,0.0,0.0,0.6049999952316284,0.6491499975323677,1.2459061443805695,2.479340438837579,-6.801201951562497,-47.89735964781622,47.213386032466225,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-26,0.6980000138282776,0.6980000138282776,0.6800000071525574,0.6800000071525574,18688,0.0,0.0,0.6129999935626984,0.6486499980092049,1.2394894773761431,10.929855512797182,-5.4960309189734335,-47.66797057589206,52.84359795788894,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-27,0.6819999814033508,0.6819999814033508,0.6800000071525574,0.6800000071525574,10259,0.0,0.0,0.6159999966621399,0.6478999987244606,1.2330728103717168,10.389612148897436,-4.923599648884572,-47.456468646880026,52.84359795788894,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-09-30,0.6499999761581421,0.7300000190734863,0.6499999761581421,0.7099999785423279,8972,0.0,0.0,0.6221999943256378,0.648149998486042,1.2271978105107944,14.111215849792929,-4.003703497804314,-47.184553872674876,55.59033672691135,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-01,0.7099999785423279,0.7099999785423279,0.6000000238418579,0.7080000042915344,2727,0.0,0.0,0.6383999943733215,0.6480999991297722,1.2150144765774409,10.902257288791962,-1.4966833466247915,-46.659071836296384,55.35883624756036,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-02,0.6039999723434448,0.699999988079071,0.6039999723434448,0.699999988079071,4539,0.0,0.0,0.6465999960899353,0.6479499995708465,1.2054311429460844,8.258582170128612,-0.20834994703377258,-46.247448196232014,54.3832428843036,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-03,0.6800000071525574,0.6800000071525574,0.5580000281333923,0.6800000071525574,2445,0.0,0.0,0.6565999984741211,0.647349999845028,1.1963061432043711,3.563814915140996,1.4289022370136013,-45.88759712367056,51.919822763011304,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-04,0.5619999766349792,0.699999988079071,0.5619999766349792,0.699999988079071,1952,0.0,0.0,0.6697999954223632,0.6479000002145767,1.189556143184503,4.508807534055634,3.380150517137444,-45.53430673056632,54.1561686393396,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-07,0.6959999799728394,0.6959999799728394,0.6499999761581421,0.6499999761581421,3536,0.0,0.0,0.674399995803833,0.647349999845028,1.1811811432242394,-3.6180337778039267,4.178573563803307,-45.194688929932155,48.12910338013281,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-08,0.6499999761581421,0.6499999761581421,0.6499999761581421,0.6499999761581421,6,0.0,0.0,0.6777999937534332,0.6460999995470047,1.1725561435023943,-4.101507502433544,4.906360351130496,-44.898160900243035,48.12910338013281,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-09,0.5839999914169312,0.6499999761581421,0.5839999914169312,0.6499999761581421,3000,0.0,0.0,0.6807999908924103,0.6455999985337257,1.1646811430652937,-4.524091531478244,5.452291269924114,-44.56851968646216,48.12910338013281,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-10,0.5640000104904175,0.6480000019073486,0.5640000104904175,0.5960000157356262,16321,0.0,0.0,0.6723999917507172,0.6429999992251396,1.1566478103399276,-11.362280926888408,4.572316105910829,-44.40831569670563,41.84706796947365,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-11,0.6959999799728394,0.6959999799728394,0.6800000071525574,0.6800000071525574,2011,0.0,0.0,0.6723999917507172,0.6422499999403953,1.1498144770661989,1.1302818999227153,4.694432357044757,-44.14316285361758,52.281126631996884,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-14,0.7059999704360962,0.7059999704360962,0.5799999833106995,0.5799999833106995,3671,0.0,0.0,0.6593999922275543,0.6399999991059303,1.1425644765297571,-12.041251115067416,3.031248929488355,-43.98565575487135,42.503894473701344,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-15,0.5799999833106995,0.6200000047683716,0.5799999833106995,0.6200000047683716,24562,0.0,0.0,0.650599992275238,0.6417499989271164,1.1345644762118658,-4.703348888747147,1.3790406486820637,-43.43644522787989,46.79042192226616,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-16,0.6200000047683716,0.6200000047683716,0.5659999847412109,0.5659999847412109,15827,0.0,0.0,0.637199991941452,0.6403999984264374,1.122947809100151,-11.173887021452316,-0.4996887090643695,-42.971526081910476,42.21479844042998,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-17,0.6480000019073486,0.6480000019073486,0.5640000104904175,0.5960000157356262,9418,0.0,0.0,0.628799992799759,0.638799998164177,1.1125811422864595,-5.216281399446179,-1.5654360352468164,-42.58396319288833,45.40875346050278,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-18,0.593999981880188,0.593999981880188,0.5699999928474426,0.5699999928474426,29545,0.0,0.0,0.6157999932765961,0.6361999973654747,1.1008311420679093,-7.43747985209569,-3.2065394802508242,-42.20730382223979,43.181124665846774,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-21,0.5640000104904175,0.5759999752044678,0.5640000104904175,0.5759999752044678,34203,0.0,0.0,0.6083999931812286,0.6323499962687492,1.0890061418215433,-5.325446801428482,-3.7874599871653722,-41.93329385534603,43.86549950103891,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-22,0.5580000281333923,0.5580000281333923,0.5580000281333923,0.5580000281333923,7126,0.0,0.0,0.5991999983787537,0.6305499970912933,1.0787811423341434,-6.875829498804323,-4.9718497910008965,-41.54977572865416,42.222449566125206,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-23,0.6660000085830688,0.6660000085830688,0.6660000085830688,0.6660000085830688,11939,0.0,0.0,0.6008000016212464,0.633399997651577,1.0680811420083045,10.852198200046875,-5.146826042185007,-40.69738967017057,53.48126525361782,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-24,0.6660000085830688,0.6660000085830688,0.5019999742507935,0.6639999747276306,9327,0.0,0.0,0.6075999975204468,0.6359499976038933,1.0577811419963836,9.28241893307214,-4.457897663379581,-39.87886790989251,53.27422771271869,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-25,0.5019999742507935,0.6700000166893005,0.5019999742507935,0.6480000019073486,6514,0.0,0.0,0.604399996995926,0.6348999977111817,1.0453478078047433,7.213766566533682,-4.803906256923673,-39.26423406918625,51.55480309278346,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-28,0.6200000047683716,0.6200000047683716,0.5080000162124634,0.5879999995231628,6584,0.0,0.0,0.6051999986171722,0.6323499977588654,1.0303311402599016,-2.842035547473535,-4.293508221383164,-38.62652762301693,45.60993602999054,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-29,0.5899999737739563,0.5899999737739563,0.5059999823570251,0.5759999752044678,15287,0.0,0.0,0.6007999956607819,0.6302999973297119,1.016714473068714,-4.127832995244642,-4.68031124764521,-38.00619406672758,44.50460215494989,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-30,0.5759999752044678,0.5759999752044678,0.5759999752044678,0.5759999752044678,0,0.0,0.0,0.6017999947071075,0.6283499971032143,1.0031811391313872,-4.287141862670917,-4.225352513488681,-37.36425331448353,44.50460215494989,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-10-31,0.460999995470047,0.5479999780654907,0.460999995470047,0.5199999809265137,16941,0.0,0.0,0.5941999912261963,0.6263499960303307,0.989347805082798,-12.487379904964794,-5.132913707654528,-36.690616503878346,39.344132652938185,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-01,0.5199999809265137,0.5680000185966492,0.5199999809265137,0.5199999809265137,6608,0.0,0.0,0.5891999900341034,0.6214499950408936,0.9760978057980537,-11.744740373058113,-5.189477072031845,-36.33322487260398,39.344132652938185,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-04,0.5099999904632568,0.5180000066757202,0.44999998807907104,0.44999998807907104,45903,0.0,0.0,0.5765999913215637,0.615449994802475,0.9626811395088831,-21.9562964183066,-6.312454920627622,-36.069174979739394,33.682206434284595,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-05,0.44999998807907104,0.6499999761581421,0.44999998807907104,0.5899999737739563,27122,0.0,0.0,0.5797999858856201,0.614949993789196,0.9524728054801623,1.7592252736529739,-5.7159132057208035,-35.43647752975097,49.37399828348114,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-06,0.6499999761581421,0.6499999761581421,0.5,0.5,1135,0.0,0.0,0.5631999850273133,0.6124499931931495,0.9425144717097282,-11.22158854891452,-8.04147419596822,-35.01956610998654,42.42443364985687,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-07,0.5099999904632568,0.6100000143051147,0.5,0.5479999780654907,24906,0.0,0.0,0.5515999853610992,0.6111499920487404,0.9331644718845685,-0.6526481854874944,-9.743926607609605,-34.50779466405371,46.73087193941928,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-08,0.6399999856948853,0.6399999856948853,0.550000011920929,0.550000011920929,28197,0.0,0.0,0.5417999863624573,0.6086499929428101,0.924164472023646,1.51347836191822,-10.983324957769963,-34.140511633167726,46.90906115115792,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-11,0.550000011920929,0.550000011920929,0.5040000081062317,0.550000011920929,9350,0.0,0.0,0.5379999876022339,0.6061999931931495,0.9154144719243049,2.230487842978761,-11.250413453763523,-33.778631233691506,46.90906115115793,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-12,0.578000009059906,0.578000009059906,0.47099998593330383,0.47099998593330383,51667,0.0,0.0,0.5274999886751175,0.6043249927461147,0.9064228055377801,-10.710901223660784,-12.712531335481684,-33.32857590806433,40.67597606507542,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-13,0.6480000019073486,0.6480000019073486,0.6380000114440918,0.6380000114440918,1219,0.0,0.0,0.5336999922990799,0.6048249937593937,0.8989478059113025,19.542818184371118,-11.75960024704404,-32.71856388299916,54.453600746747284,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-14,0.5120000243186951,0.6100000143051147,0.5120000243186951,0.5120000243186951,4168,0.0,0.0,0.532899996638298,0.6031249947845936,0.8900894723832607,-3.9219314039119144,-11.643523109397327,-32.23995862239612,45.809196478253845,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-15,0.5120000243186951,0.5120000243186951,0.5120000243186951,0.5120000243186951,2368,0.0,0.0,0.5321000009775162,0.6017249949276448,0.8809811390936375,-3.777481041513933,-11.5708994203408,-31.698311322906907,45.809196478253845,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-18,0.6340000033378601,0.6340000033378601,0.4519999921321869,0.4699999988079071,8896,0.0,0.0,0.5341000020503998,0.5983749955892563,0.8718978062272071,-12.00149840786631,-10.741590810552013,-31.370971309299716,43.160435873694475,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-19,0.4699999988079071,0.4699999988079071,0.4699999988079071,0.4699999988079071,6785,0.0,0.0,0.5221000045537949,0.5947249956429005,0.8620228064556916,-9.978932252723174,-12.21152492684415,-31.008206373543363,43.160435873694475,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-20,0.4699999988079071,0.4699999988079071,0.4690000116825104,0.4690000116825104,1370,0.0,0.0,0.5190000057220459,0.5909499958157539,0.8522644733389219,-9.6339101133485,-12.175309349886279,-30.661195637947287,43.091634482029974,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-21,0.453000009059906,0.5860000252723694,0.453000009059906,0.5860000252723694,2196,0.0,0.0,0.5228000104427337,0.5885999962687493,0.8436061402161916,12.088755464276803,-11.179066640016062,-30.22810430020006,52.610217525238134,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-22,0.5860000252723694,0.5860000252723694,0.578000009059906,0.578000009059906,2270,0.0,0.0,0.5256000101566315,0.586049996316433,0.8332561398545901,9.969558198383414,-10.314817257871285,-29.667485388262083,51.97012960817063,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-25,0.6320000290870667,0.6320000290870667,0.46000000834465027,0.5,23761,0.0,0.0,0.5206000089645386,0.5807999968528748,0.8222978060444196,-3.9569743776054787,-10.365011744927005,-29.368655420989825,46.08305832371683,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-26,0.5,0.5,0.5,0.5,1548,0.0,0.0,0.5235000103712082,0.5755999967455864,0.8123394722739855,-4.489018129062612,-9.05142228439001,-29.142924061746413,46.08305832371683,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-27,0.6980000138282776,0.6980000138282776,0.5680000185966492,0.5680000185966492,5664,0.0,0.0,0.5165000110864639,0.5722999975085259,0.8037394722302754,9.970959613699595,-9.75012872007407,-28.795335145048213,51.623720880580734,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-28,0.44999998807907104,0.5640000104904175,0.44999998807907104,0.5640000104904175,31856,0.0,0.0,0.5217000097036362,0.5693999975919724,0.7949811389048894,8.108108108108109,-8.377237107492514,-28.375659531201197,51.28983024691284,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-11-29,0.4320000112056732,0.5,0.4320000112056732,0.47999998927116394,9423,0.0,0.0,0.518500006198883,0.5638999976217747,0.7846478052437306,-7.425268364018398,-8.051071398184831,-28.13336201882146,44.7449439178301,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-02,0.4300000071525574,0.44200000166893005,0.4300000071525574,0.44200000166893005,20333,0.0,0.0,0.5157000064849854,0.5586999982595444,0.7741228049000104,-14.291255359563603,-7.69643671174371,-27.827988695965505,42.126093028607976,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-03,0.44200000166893005,0.44200000166893005,0.4099999964237213,0.4099999964237213,25490,0.0,0.0,0.5097000062465668,0.5526999987661838,0.7637061384816964,-19.560527486949976,-7.779987808143261,-27.629231858081987,40.00280678566328,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-04,0.41499999165534973,0.453000009059906,0.41499999165534973,0.453000009059906,1236,0.0,0.0,0.5081000059843064,0.547774999588728,0.7541478050251802,-10.844321250825224,-7.242936175292735,-27.365034289208285,44.08145670021162,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-05,0.41499999165534973,0.47999998927116394,0.41499999165534973,0.47999998927116394,17352,0.0,0.0,0.4975000023841858,0.5448749989271164,0.7448978046576182,-3.5175905586243132,-8.69465411997507,-26.852382230128796,46.539005094871676,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-06,0.4699999988079071,0.4699999988079071,0.4699999988079071,0.4699999988079071,469,0.0,0.0,0.4867000013589859,0.5396249987185001,0.7357311375439167,-3.4312723452739426,-9.807736388269698,-26.654592801396937,45.73725839462256,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-09,0.44999998807907104,0.4690000116825104,0.41499999165534973,0.4690000116825104,8327,0.0,0.0,0.48360000252723695,0.5368499994277954,0.7266394714514415,-3.0190220778388612,-9.918971213060498,-26.11879473661774,45.65256203426995,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-10,0.4490000009536743,0.4490000009536743,0.4490000009536743,0.4490000009536743,144,0.0,0.0,0.4785000026226044,0.532574999332428,0.7175061384836833,-6.165099583541045,-10.153498902052394,-25.77415428696862,43.901527334298315,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-11,0.4699999988079071,0.4699999988079071,0.4000000059604645,0.41999998688697815,2419,0.0,0.0,0.46369999945163726,0.5289249993860722,0.7083394718666871,-9.424199399684689,-12.331616015530017,-25.328882492995053,41.42068298949217,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-12,0.41999998688697815,0.41999998688697815,0.4009999930858612,0.4050000011920929,13820,0.0,0.0,0.4477999985218048,0.5241499990224838,0.6989644721150399,-9.557837755916793,-14.566441027009128,-25.0104948200835,40.15666051610978,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-13,0.41499999165534973,0.41499999165534973,0.38999998569488525,0.41499999165534973,28635,0.0,0.0,0.4412999987602234,0.5202749989926815,0.6899228053788344,-5.959666253967874,-15.179472468476037,-24.589389575693165,41.439683335139726,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-16,0.39500001072883606,0.39500001072883606,0.3700000047683716,0.3709999918937683,41494,0.0,0.0,0.43419999778270724,0.515149999409914,0.6803894720971584,-14.555505806466398,-15.713870080545886,-24.286012565410253,37.618021288767714,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-17,0.3700000047683716,0.41499999165534973,0.36500000953674316,0.41499999165534973,51904,0.0,0.0,0.43469999730587006,0.511574998497963,0.6698061391711235,-4.53186238155385,-15.027122400001142,-23.62342346831422,43.25383997945115,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-18,0.4000000059604645,0.4000000059604645,0.4000000059604645,0.4000000059604645,10000,0.0,0.0,0.4293999969959259,0.5049249984323978,0.6598478056490421,-6.8467608852219835,-14.957667311174653,-23.478566707402855,41.86524881460428,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-19,0.36399999260902405,0.44999998807907104,0.36399999260902405,0.44999998807907104,25458,0.0,0.0,0.4263999968767166,0.49957499876618383,0.6505561384061972,5.534707170548557,-14.64745074717307,-23.20801091968839,47.872556075224466,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-20,0.4000000059604645,0.4000000059604645,0.4000000059604645,0.4000000059604645,18762,0.0,0.0,0.41939999759197233,0.49337499886751174,0.6410144721468289,-4.625653729827104,-14.993666368450148,-23.03215913126831,43.07863733427969,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-23,0.39500001072883606,0.39500001072883606,0.39500001072883606,0.39500001072883606,16642,0.0,0.0,0.41199999749660493,0.48854999914765357,0.6313061393797398,-4.126210405598112,-15.668816249022871,-22.612823054808963,42.619024674033895,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-27,0.39500001072883606,0.39500001072883606,0.35600000619888306,0.35899999737739563,21160,0.0,0.0,0.40299999713897705,0.48312499970197675,0.621381139755249,-10.918114162270763,-16.584735340217556,-22.249812749020496,39.36266564357033,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2024-12-30,0.35899999737739563,0.4000000059604645,0.35899999737739563,0.4000000059604645,43599,0.0,0.0,0.40099999904632566,0.4787250004708767,0.6130385480821132,-0.24937483497242086,-16.23583505104188,-21.909478291607524,44.55822018420529,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-02,0.6380000114440918,0.6380000114440918,0.41499999165534973,0.41499999165534973,5146,0.0,0.0,0.40199999809265136,0.4761000007390976,0.6048610811432202,3.233829259795715,-15.563957683556689,-21.2877112478054,46.36873235960763,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-03,0.41499999165534973,0.6000000238418579,0.41499999165534973,0.5,8199,0.0,0.0,0.4104999989271164,0.47560000121593476,0.5969907149672509,21.802679977296215,-13.687973532880893,-20.333769137092066,55.28067414186853,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-07,0.5899999737739563,0.5899999737739563,0.5699999928474426,0.5699999928474426,21758,0.0,0.0,0.4303999990224838,0.478600001335144,0.5945345481236776,32.434942876862365,-10.071040990011971,-19.50005212555223,61.024597058609096,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-08,0.5699999928474426,0.5699999928474426,0.40299999713897705,0.5600000023841858,2177,0.0,0.0,0.44490000009536745,0.4778500020503998,0.592797514796257,25.8709827521119,-6.895469669069298,-19.390687355591286,59.84208295150691,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-09,0.5600000023841858,0.5600000023841858,0.5600000023841858,0.5600000023841858,250,0.0,0.0,0.46089999973773954,0.47935000211000445,0.5908999900023143,21.50141087065219,-3.8489626141757847,-18.877981008575233,59.84208295150691,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-10,0.5699999928474426,0.5699999928474426,0.5699999928474426,0.5699999928474426,20844,0.0,0.0,0.47290000021457673,0.4799000024795532,0.5895833318432172,20.532880648933624,-1.4586376805186065,-18.603532942622454,60.72473573002526,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-13,0.5699999928474426,0.5799999833106995,0.550000011920929,0.550000011920929,29752,0.0,0.0,0.4879000008106232,0.4799000024795532,0.5883166650931041,12.728020292504509,1.6670136048625688,-18.42828344772341,57.9799332077806,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-14,0.5680000185966492,0.5799999833106995,0.5260000228881836,0.5260000228881836,64365,0.0,0.0,0.5010000020265579,0.4793000027537346,0.5859166651964187,4.990024103892204,4.527435666211096,-18.196557424585748,54.78005060715669,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-15,0.5260000228881836,0.5299999713897705,0.5099999904632568,0.527999997138977,24791,0.0,0.0,0.517900002002716,0.48072500303387644,0.5837666650613149,1.9501824864268034,7.733111182947952,-17.651172667869904,55.00291401562691,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-16,0.4909999966621399,0.527999997138977,0.4729999899864197,0.4729999899864197,28023,0.0,0.0,0.5252000004053116,0.4766000024974346,0.5814749980966251,-9.939072806284782,10.197229889468694,-18.03602836622102,47.99726729333316,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-17,0.5,0.5059999823570251,0.5,0.5059999823570251,9732,0.0,0.0,0.5342999994754791,0.4764500014483929,0.5795249978701273,-5.296653031300024,12.14188222294555,-17.786117389337146,51.951633943845444,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-20,0.30799999833106995,0.30799999833106995,0.10000000149011612,0.20100000500679016,3896108,0.0,0.0,0.5043999999761581,0.4686750009655952,0.5753666646778584,-60.150673073693305,7.622552714985846,-18.543247334636366,29.57055862754956,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-21,0.21799999475479126,0.23499999940395355,0.20600000023841858,0.23000000417232513,675536,0.0,0.0,0.4704000011086464,0.4626750010997057,0.5713499979426463,-51.10544140513235,1.6696385131203444,-19.020739867728096,32.54613720977282,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-22,0.2280000001192093,0.25,0.20499999821186066,0.23499999940395355,255288,0.0,0.0,0.4379000008106232,0.45680000111460684,0.5673749978343646,-46.3347798655102,-4.137478165032187,-19.488873697610178,33.071170328680026,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-23,0.25,0.25,0.17000000178813934,0.20900000631809235,353871,0.0,0.0,0.4028000012040138,0.4503000009804964,0.563466664776206,-48.1132061337219,-10.548523134144942,-20.084003343952283,31.68986834606872,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-24,0.20999999344348907,0.20999999344348907,0.1599999964237213,0.17350000143051147,634283,0.0,0.0,0.36315000206232073,0.43998750038444995,0.559079164887468,-52.22359894115136,-17.46356390919982,-21.301395577313087,29.85622912512906,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-27,0.17000000178813934,0.1835000067949295,0.1599999964237213,0.17100000381469727,189492,0.0,0.0,0.32525000125169756,0.42981250025331974,0.5545874984314044,-47.42505667744259,-24.32746812621687,-22.498703726823692,29.7257855598631,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-28,0.17100000381469727,0.20000000298023224,0.1509999930858612,0.16349999606609344,533798,0.0,0.0,0.28899999856948855,0.4214000001549721,0.5501166651646296,-43.42560661750982,-31.41907962429823,-23.39806683935623,29.31203323154277,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-29,0.15000000596046448,0.1599999964237213,0.14000000059604645,0.14749999344348907,250820,0.0,0.0,0.25094999819993974,0.4125874999910593,0.5454291652888059,-41.22335345626455,-39.17653874502311,-24.355438570544106,28.403740838967977,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-30,0.14749999344348907,0.14749999344348907,0.13249999284744263,0.1459999978542328,12747,0.0,0.0,0.21824999898672104,0.4020374994724989,0.5407624988506238,-33.10423893146691,-45.714019395434455,-25.653590933724352,28.315157239826704,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-01-31,0.15000000596046448,0.18000000715255737,0.14749999344348907,0.18000000715255737,300381,0.0,0.0,0.18565000146627425,0.39243749938905237,0.5363958322753509,-3.0433580765380563,-52.693103550171784,-26.83807819230028,33.38640023409877,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-03,0.18000000715255737,0.18000000715255737,0.1599999964237213,0.17100000381469727,217801,0.0,0.0,0.18265000134706497,0.3847124997526407,0.532170832529664,-6.378317791649393,-52.52298756486889,-27.708834036634983,32.72641557196046,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-04,0.17000000178813934,0.17000000178813934,0.17000000178813934,0.17000000178813934,45300,0.0,0.0,0.1766500011086464,0.37791249975562097,0.527987499286731,-3.76450567719898,-53.25637516015532,-28.423968320054815,32.64918673257931,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-05,0.17149999737739563,0.17149999737739563,0.15049999952316284,0.15449999272823334,29005,0.0,0.0,0.16860000044107437,0.37152499966323377,0.5234416659921408,-8.362993876603802,-54.61947363060342,-29.02265451890641,31.411843334979977,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-06,0.15049999952316284,0.1599999964237213,0.15000000596046448,0.15000000596046448,25095,0.0,0.0,0.16270000040531157,0.3639499995857477,0.5191083325694005,-7.805774070810935,-55.29605698846032,-29.88939364846535,31.044002821788922,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-07,0.15049999952316284,0.1720000058412552,0.15049999952316284,0.15150000154972076,107958,0.0,0.0,0.1605000004172325,0.35573749989271164,0.5145374993483226,-5.607475915336776,-54.88246235900394,-30.862667863223965,31.33265829774905,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-10,0.1509999930858612,0.1509999930858612,0.15000000596046448,0.15000000596046448,115587,0.0,0.0,0.15840000063180923,0.3477375000715256,0.5098708329101403,-5.3030269178281175,-54.44839840419047,-31.79890324638145,31.192041810304246,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-11,0.14100000262260437,0.15399999916553497,0.14000000059604645,0.14249999821186066,38952,0.0,0.0,0.15630000084638596,0.33957499973475935,0.5054749994228284,-8.829176301853098,-53.971876325267985,-32.82061424946838,30.456056600273257,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-12,0.15449999272823334,0.15449999272823334,0.1404999941587448,0.1404999941587448,6314,0.0,0.0,0.15560000091791154,0.3318624995648861,0.5020624992748102,-9.704374466638274,-53.11311126688827,-33.90016182363044,30.251072626468854,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-13,0.15449999272823334,0.15449999272823334,0.14399999380111694,0.14399999380111694,10358,0.0,0.0,0.15540000051259995,0.32496249973773955,0.4980958325167497,-7.335911630552847,-52.1790973918482,-34.759040625618596,31.124710557494623,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-14,0.14499999582767487,0.2809999883174896,0.14399999380111694,0.23399999737739563,2107684,0.0,0.0,0.16079999953508378,0.32068749964237214,0.4945458322763443,45.522386849473136,-49.85772762754815,-35.155150703367546,48.862292453718815,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-17,0.23499999940395355,0.23499999940395355,0.15800000727176666,0.19499999284744263,476068,0.0,0.0,0.1631999984383583,0.31518749967217446,0.49055416534344354,19.48529087829335,-48.221297288724294,-35.74868547869582,43.619976221497694,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-18,0.051945000886917114,0.051945000886917114,0.042222000658512115,0.04794999957084656,536846,0.0,0.0,0.15099499821662904,0.30711124986410143,0.48487041518092155,-68.2439814979475,-50.83377822093941,-36.661169613842524,30.38350364603606,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-19,0.04821600019931793,0.04821600019931793,0.04275500029325485,0.04821600019931793,88625,0.0,0.0,0.1403665989637375,0.2979416500777006,0.48002221522231897,-65.6499476689792,-52.88788964982537,-37.93169552794322,30.424632318041517,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-20,0.048082999885082245,0.048082999885082245,0.03995800018310547,0.04448600113391876,1386141,0.0,0.0,0.12981519848108292,0.28905379995703695,0.4757929320136706,-65.73128443014983,-55.08960667516642,-39.2479836273121,30.155595831902616,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-21,0.04448600113391876,0.04448600113391876,0.032632000744342804,0.0362280011177063,1474215,0.0,0.0,0.11828799843788147,0.27870950028300284,0.47141149888436,-69.3730542437648,-57.558677290235416,-40.877661885084414,29.532946590465386,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-24,0.03356499969959259,0.03689400106668472,0.026637999340891838,0.036761000752449036,781927,0.0,0.0,0.10696409791707992,0.26962852515280245,0.4659678405771653,-65.63239304748151,-60.329086895957396,-42.13580816675451,29.63393592820509,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-25,0.03689400106668472,0.03689400106668472,0.03449700027704239,0.03449700027704239,347011,0.0,0.0,0.0961637981235981,0.2606159498915076,0.4605053155993422,-64.12683260211516,-63.10133813236284,-43.406527337839954,29.440927980419602,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-26,0.03249900043010712,0.033032000064849854,0.03249900043010712,0.033032000064849854,136248,0.0,0.0,0.0854169987142086,0.252466749958694,0.45529724899679425,-61.328540498865394,-66.16703041957658,-44.54902802180744,29.3079081058939,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-27,0.10999999940395355,0.16949999332427979,0.10999999940395355,0.1379999965429306,1246516,0.0,0.0,0.08481699898838997,0.24591674972325564,0.45099724909911554,62.70322952810496,-65.5098731242018,-45.472671903324496,47.58242385050559,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-02-28,0.14000000059604645,0.20999999344348907,0.10999999940395355,0.125,1195599,0.0,0.0,0.0739169992506504,0.2386667499318719,0.44703891556710007,69.10859648959588,-69.02920106309311,-46.61163902719599,45.99654055158312,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-03,0.12399999797344208,0.12399999797344208,0.07000000029802322,0.07760000228881836,1861767,0.0,0.0,0.06217700019478798,0.22810674998909236,0.4417189154153069,24.80499548983262,-72.74214805227764,-48.359297727917095,40.67354115944231,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-04,0.07999999821186066,0.07999999821186066,0.06700000166893005,0.07180000096559525,637795,0.0,0.0,0.06456200033426285,0.21565175019204616,0.43656724877655506,11.210929949286614,-70.06191682804896,-50.602856536674935,40.062592449944454,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-05,0.07000000029802322,0.07440000027418137,0.06520000100135803,0.0697999969124794,79519,0.0,0.0,0.066720400005579,0.2033967500552535,0.43206558196494976,4.615675125812941,-67.19691932764209,-52.92456549530169,39.84036202870431,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-06,0.0697999969124794,0.07440000027418137,0.06080000102519989,0.06880000233650208,80609,0.0,0.0,0.06915180012583733,0.19111675005406142,0.4276389151190718,-0.5087326558311935,-63.81698615831617,-55.30884975684525,39.721718530868955,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-07,0.06319999694824219,0.0722000002861023,0.06300000101327896,0.06499999761581421,141959,0.0,0.0,0.07202899977564811,0.1784917501732707,0.42318058156718813,-9.758572494033576,-59.64575410027296,-57.82137509423227,39.243463909482884,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-10,0.06199999898672104,0.07460000365972519,0.06019999831914902,0.07460000365972519,243389,0.0,0.0,0.07581290006637573,0.1666067499667406,0.418385581796368,-1.5998549133308744,-54.49590122758525,-60.178658821988364,41.170536555252085,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-11,0.07000000029802322,0.07440000027418137,0.06520000100135803,0.07440000027418137,76977,0.0,0.0,0.07980320006608962,0.15531674940139056,0.41360558178275825,-6.770655546937414,-48.619063704551664,-62.44810122437637,41.141259109539845,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-12,0.06560000032186508,0.07440000027418137,0.06560000032186508,0.07440000027418137,13890,0.0,0.0,0.08394000008702278,0.14397674947977065,0.4096755817532539,-11.365260665893551,-41.69891986704651,-64.85591138636929,41.141259109539845,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-13,0.07440000027418137,0.07440000027418137,0.06520000100135803,0.07419999688863754,39684,0.0,0.0,0.07756000012159348,0.13400674965232612,0.4051439153030515,-4.33213412543623,-42.12231822440358,-66.92366722277248,41.1073563092386,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-14,0.07419999688863754,0.07419999688863754,0.06520000100135803,0.07400000095367432,92136,0.0,0.0,0.0724600002169609,0.12320675011724233,0.4009272487834096,2.1253115265005755,-41.1882870475776,-69.26954940301361,41.07090939068592,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-17,0.07460000365972519,0.07460000365972519,0.06539999693632126,0.06560000032186508,119408,0.0,0.0,0.07126000002026558,0.11982175000011921,0.39674058196445305,-7.942744452414903,-40.52832643472935,-69.79846392148133,39.48732288095181,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-18,0.06560000032186508,0.07440000027418137,0.06560000032186508,0.07119999825954437,16423,0.0,0.0,0.07119999974966049,0.11585174985229969,0.3923005821804206,-2.0928597177990246e-06,-38.542145595181836,-70.46862658005972,41.117325250264116,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-19,0.0714000016450882,0.07440000027418137,0.06499999761581421,0.06499999761581421,210226,0.0,0.0,0.07071999981999397,0.11160174980759621,0.38770891552170117,-8.088238431474936,-36.63181810149326,-71.21506745403963,39.83786592092561,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-20,0.06560000032186508,0.07339999824762344,0.06560000032186508,0.06599999964237213,56894,0.0,0.0,0.07043999955058097,0.1080267496407032,0.38309224881231785,-6.303236707178857,-34.79392855485859,-71.80137421845177,40.16129394887397,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-21,0.07000000029802322,0.07440000027418137,0.07000000029802322,0.07020000368356705,25929,0.0,0.0,0.07096000015735626,0.10544424969702959,0.37801058211674293,-1.0710209584327741,-32.70377440093328,-72.10547675502251,41.581777693109196,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-24,0.07280000299215317,0.07419999688863754,0.06520000100135803,0.07419999688863754,176067,0.0,0.0,0.07091999948024749,0.10302424952387809,0.3729622486978769,4.624925877648363,-31.161838297293055,-72.37676202254607,42.97028916582623,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-25,0.07419999688863754,0.07419999688863754,0.06539999693632126,0.07360000163316727,398487,0.0,0.0,0.0708399996161461,0.10077674966305494,0.3676589155569673,3.8961067645066794,-29.70600872423627,-72.58960808542123,42.80593588494053,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-26,0.07360000163316727,0.07360000163316727,0.0560000017285347,0.0560000017285347,1039966,0.0,0.0,0.06899999976158142,0.09848924987018108,0.3622255822022756,-18.84057692458863,-29.941592760092618,-72.80996850874484,38.19142667974705,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-27,0.05820000171661377,0.05959999933838844,0.04600000008940697,0.04879999905824661,559813,0.0,0.0,0.06645999997854232,0.09605924990028143,0.35679891562710203,-26.57237575383317,-30.813534305614425,-73.07748266794763,36.459852494109164,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-28,0.04859999939799309,0.05260000005364418,0.04859999939799309,0.05260000005364418,560819,0.0,0.0,0.06431999988853931,0.0928742497228086,0.35157058223461113,-18.22139280970899,-30.74506649527933,-73.58304294617247,38.05613321704478,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-03-31,0.05260000005364418,0.05260000005364418,0.04600000008940697,0.052400000393390656,55058,0.0,0.0,0.06299999989569187,0.08990924963727594,0.34617391567056377,-16.8253960632563,-29.929345256628213,-74.02772260783564,38.002020670659675,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-01,0.052400000393390656,0.05260000005364418,0.04619999974966049,0.05000000074505806,228252,0.0,0.0,0.06088000014424324,0.0869092496111989,0.34117391587545476,-17.871221046989408,-29.9499185453807,-74.52640850687864,37.31631356527563,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-02,0.04479999840259552,0.04479999840259552,0.03460000082850456,0.03999999910593033,4027770,0.0,0.0,0.05838000029325485,0.08404674977064133,0.33609058273335296,-31.48338659643365,-30.538658005728408,-74.99282809797671,34.52124785521953,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-03,0.04399999976158142,0.04399999976158142,0.03400000184774399,0.03480000048875809,867201,0.0,0.0,0.05526000037789345,0.08116674963384866,0.33096391626944144,-37.024972401774185,-31.91793360313571,-75.47564986880022,33.1315423355629,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-04,0.03500000014901161,0.03779999911785126,0.030400000512599945,0.03440000116825104,1337309,0.0,0.0,0.05168000012636185,0.07823924962431192,0.32628391614804664,-33.43653040994542,-33.946196602705015,-76.02111359089733,33.02142067309093,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-07,0.03440000116825104,0.03440000116825104,0.027799999341368675,0.03220000118017197,3312598,0.0,0.0,0.04748000055551529,0.07529424950480461,0.32088558276494344,-32.18196966421137,-36.94073469384201,-76.53548381450359,32.383879713827895,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-08,0.03440000116825104,0.038600001484155655,0.032999999821186066,0.03759999945759773,1623435,0.0,0.0,0.04388000033795834,0.07267174953594804,0.31636558289950095,-14.311761239728382,-39.61890195549439,-77.0291860227307,35.66710769876536,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-09,0.035999998450279236,0.035999998450279236,0.03440000116825104,0.03579999879002571,384813,0.0,0.0,0.041860000044107434,0.07005424965173006,0.31149724951634805,-14.476830500946884,-40.24630875041617,-77.51047569103704,35.05605652642335,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-10,0.03579999879002571,0.03999999910593033,0.03579999879002571,0.03779999911785126,358567,0.0,0.0,0.0407600000500679,0.06739924978464842,0.3070955829694867,-7.262023867960497,-39.524549338007866,-78.05268016787292,36.360656788493564,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-11,0.03779999911785126,0.038600001484155655,0.03519999980926514,0.03519999980926514,169308,0.0,0.0,0.03902000002563,0.06242924984544516,0.3024222495034337,-9.78985190634475,-37.49724668768081,-79.35692564024251,35.36604600837647,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-14,0.039000000804662704,0.039000000804662704,0.03799999877810478,0.039000000804662704,62677,0.0,0.0,0.0376800000667572,0.05852925004437566,0.2979972495697439,3.5031866655171786,-35.62193255818414,-80.35913078765603,38.03395129717583,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-15,0.039000000804662704,0.039000000804662704,0.03500000014901161,0.03579999879002571,898479,0.0,0.0,0.036259999871253966,0.05822550002485514,0.29349558309962354,-1.2686185407102892,-37.724880240143236,-80.16137094468941,36.66157860067717,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-16,0.03700000047683716,0.03700000047683716,0.032999999821186066,0.03660000115633011,37298,0.0,0.0,0.035920000076293944,0.05793510004878044,0.28915058287481465,1.893098771135426,-37.99958911601107,-79.96369245644476,37.27096802355885,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-17,0.032999999821186066,0.03680000081658363,0.032999999821186066,0.03660000115633011,62401,0.0,0.0,0.03610000014305115,0.05773795004934072,0.28390558281292516,1.3850443526250398,-37.47613118892961,-79.6629747547493,37.27096802355885,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-22,0.032999999821186066,0.05959999933838844,0.03099999949336052,0.04019999876618385,4707675,0.0,0.0,0.03667999990284443,0.05783724999055266,0.2787072496799131,9.596507286431203,-36.580664003153906,-79.24802815248724,40.270127583333625,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-23,0.04100000113248825,0.05000000074505806,0.03799999877810478,0.04320000112056732,2941231,0.0,0.0,0.037779999896883965,0.05799822499975562,0.2736672496733566,14.346218206661218,-34.860075636723096,-78.80702748721995,42.72755541753394,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-24,0.04340000078082085,0.04340000078082085,0.040800001472234726,0.040800001472234726,142501,0.0,0.0,0.038100000098347665,0.05815580002963543,0.26910724968959887,7.086617760938418,-34.486327969123614,-78.38935959669793,41.26489276379588,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-25,0.0406000018119812,0.04320000112056732,0.03959999978542328,0.03959999978542328,1415777,0.0,0.0,0.03848000019788742,0.05832000002264977,0.26463724989444015,2.910601823742572,-34.01920407588662,-77.96228609316613,40.51803168422792,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-28,0.04320000112056732,0.04320000112056732,0.03959999978542328,0.04259999841451645,170875,0.0,0.0,0.03896000012755394,0.05593500006943941,0.26019225008785724,9.342911383586387,-30.347724896419393,-78.50243423831715,43.28182303666173,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-29,0.04259999841451645,0.04259999841451645,0.03999999910593033,0.04019999876618385,301858,0.0,0.0,0.03946000002324581,0.053815000038594005,0.2561939169031878,1.8753135897164503,-26.674718953922422,-78.99442707731036,41.61590337455215,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-04-30,0.04320000112056732,0.04320000112056732,0.04039999842643738,0.04039999842643738,86252,0.0,0.0,0.03959999978542328,0.05288499994203448,0.25219725038235385,2.0201985993660987,-25.120544901526813,-79.03030272461098,41.81688125828181,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-02,0.04280000180006027,0.04320000112056732,0.03959999978542328,0.04179999977350235,216658,0.0,0.0,0.040199999883770945,0.05213499991223216,0.2487955838131408,3.9800992396951145,-22.892490742406174,-79.04504609238224,43.288544282689244,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-05,0.041999999433755875,0.0430000014603138,0.03920000046491623,0.04019999876618385,675990,0.0,0.0,0.04055999964475632,0.05139499995857477,0.24421391735474268,-0.8875761383765338,-21.081817924995903,-78.95492586365627,41.98162982463348,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-06,0.04039999842643738,0.0430000014603138,0.04039999842643738,0.0430000014603138,71270,0.0,0.0,0.04119999967515468,0.050749999936670065,0.24040558403357865,4.3689364061927165,-18.81773452893131,-78.88984145660213,45.10504346803971,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-07,0.0430000014603138,0.0430000014603138,0.03999999910593033,0.04280000180006027,334415,0.0,0.0,0.04145999997854233,0.050195000041276215,0.23619558423136672,3.232035268237974,-17.40213179709323,-78.7485442606296,44.91902767532711,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-08,0.04280000180006027,0.0430000014603138,0.04280000180006027,0.0430000014603138,273640,0.0,0.0,0.04144000001251698,0.04940499998629093,0.2319705841441949,3.7644822570598926,-16.1218499665704,-78.70204096413347,45.162576722477255,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-09,0.04280000180006027,0.0430000014603138,0.03920000046491623,0.0430000014603138,281803,0.0,0.0,0.04166000001132488,0.04862000001594424,0.22774558405702314,3.2165181195982933,-14.31509667284436,-78.65161679544542,45.162576722477255,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-12,0.0430000014603138,0.04479999840259552,0.041999999433755875,0.04479999840259552,260951,0.0,0.0,0.04217999987304211,0.047879999969154596,0.22419391749426723,6.211471165100442,-11.904762113167422,-78.64348841204449,47.581815249174504,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-13,0.04580000042915344,0.047600001096725464,0.04560000076889992,0.047600001096725464,151800,0.0,0.0,0.04268000014126301,0.04721500007435679,0.21927391740803917,11.527649810632962,-9.60499825468985,-78.4675712312395,51.18917274417919,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-14,0.047600001096725464,0.050599999725818634,0.044199999421834946,0.04919999837875366,401724,0.0,0.0,0.043580000102519986,0.046595000009983775,0.21541725052520633,12.89581978662892,-6.4706511574584695,-78.36988453971023,53.17232159547273,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-15,0.04439999908208847,0.04780000075697899,0.04439999908208847,0.04780000075697899,86780,0.0,0.0,0.04432000033557415,0.04615000002086163,0.21154891699552536,7.85198645093773,-3.9653297604772395,-78.18471459164323,51.211668295213116,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-16,0.04500000178813934,0.04500000178813934,0.04399999976158142,0.04399999976158142,305421,0.0,0.0,0.04454000033438206,0.04547000005841255,0.20799891700347264,-1.2123946312227412,-2.0453039868831646,-78.13930922647381,46.228908854711655,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-19,0.04500000178813934,0.04500000178813934,0.042399998754262924,0.04479999840259552,348130,0.0,0.0,0.04500000029802322,0.04496500007808209,0.20445558366676173,-0.4444486535625384,0.0778388076956675,-78.0074482331724,47.389459199945726,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-20,0.04699999839067459,0.04879999905824661,0.04500000178813934,0.04879999905824661,242369,0.0,0.0,0.045580000057816504,0.04453500006347895,0.20095391689489286,7.064499772588112,2.346469053212172,-77.83820253338351,52.867114062446085,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-21,0.04919999837875366,0.052400000393390656,0.04619999974966049,0.05180000141263008,600749,0.0,0.0,0.046480000019073486,0.04407500000670552,0.19650225002939503,11.445786126018684,5.4566080816836555,-77.57023138406187,56.523272149292424,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-22,0.052799999713897705,0.052799999713897705,0.050200000405311584,0.050200000405311584,263833,0.0,0.0,0.047199999913573265,0.04347500009462237,0.19210391662394008,6.355933256846494,8.568142175603251,-77.36901940436309,54.1123633642113,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-23,0.050999999046325684,0.05400000140070915,0.04919999837875366,0.05380000174045563,343709,0.0,0.0,0.04827999994158745,0.042980000097304585,0.18838558330511054,11.433309456393257,12.331316501358607,-77.18509062994809,58.41071577457031,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-26,0.049800001084804535,0.055799998342990875,0.04659999907016754,0.052799999713897705,1526295,0.0,0.0,0.049080000072717664,0.042900000046938655,0.18465891663605968,7.579461360367633,14.405594449923582,-76.76797804923261,56.81858176491417,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-27,0.04919999837875366,0.04919999837875366,0.04899999871850014,0.04899999871850014,159567,0.0,0.0,0.04921999983489513,0.042905000038444996,0.18033391647040845,-0.4469750449674377,14.718563782290142,-76.20802515788237,51.116709375903056,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-28,0.04899999871850014,0.04899999871850014,0.03480000048875809,0.04100000113248825,1092089,0.0,0.0,0.04840000011026859,0.042615000065416096,0.17597558305909236,-15.289254051489868,13.575032350046321,-75.78357217256325,41.64229119203013,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-05-30,0.0430000014603138,0.0430000014603138,0.04100000113248825,0.04100000113248825,156532,0.0,0.0,0.04772000014781952,0.04233000008389354,0.1723172498246034,-14.082143743744993,12.73328621130068,-75.43484466762325,41.64229119203013,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-02,0.03999999910593033,0.044199999421834946,0.039000000804662704,0.04399999976158142,373921,0.0,0.0,0.04772000014781952,0.042180000059306624,0.16900058314204217,-7.795474381213046,13.134187009775847,-75.0415062036472,45.99559905572638,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-03,0.04399999976158142,0.04399999976158142,0.039799999445676804,0.04340000078082085,64479,0.0,0.0,0.04758000038564205,0.04226500010117888,0.1659455831783513,-8.785202965409345,12.575417654653972,-74.53080745405906,45.2682728867011,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-04,0.04340000078082085,0.07999999821186066,0.04340000078082085,0.04859999939799309,2253591,0.0,0.0,0.0475600004196167,0.04261000007390976,0.16257558309783537,2.1867093549213403,11.616992107770118,-73.79065216191304,52.30715318137689,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-05,0.049800001084804535,0.049800001084804535,0.04520000144839287,0.04879999905824661,127234,0.0,0.0,0.04726000018417835,0.04297000002115965,0.15898224984606107,3.2585672197771633,9.983709939274329,-72.97182543160224,52.55986239700945,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-09,0.04879999905824661,0.04879999905824661,0.04439999908208847,0.04740000143647194,169462,0.0,0.0,0.04698000028729439,0.04335000002756715,0.1554605832012991,0.893999886354059,8.373703015960437,-72.11511809946376,50.54105512306313,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-10,0.04740000143647194,0.052799999713897705,0.044599998742341995,0.052799999713897705,256392,0.0,0.0,0.04688000008463859,0.04373000003397465,0.15199224976822734,12.627985534494373,7.20329304417254,-71.22879613884365,57.3463621738536,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-11,0.04659999907016754,0.05260000005364418,0.04659999907016754,0.052400000393390656,23227,0.0,0.0,0.04684000015258789,0.04414500007405877,0.14868724976355832,11.870196888749527,6.104881807697187,-70.3101643589091,56.72374926307263,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-12,0.04600000008940697,0.05180000141263008,0.04600000008940697,0.05180000141263008,21643,0.0,0.0,0.04712000042200089,0.04449500013142824,0.14561891655127207,9.932090298632607,5.899539909695433,-69.44421701162592,55.74605662941905,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-13,0.05040000006556511,0.05040000006556511,0.049400001764297485,0.049400001764297485,27698,0.0,0.0,0.04796000048518181,0.04485000018030405,0.1426555832227071,3.0025047217432688,6.934225846990115,-68.56064153459289,51.89311438455516,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-16,0.049400001764297485,0.05260000005364418,0.047200001776218414,0.050599999725818634,186066,0.0,0.0,0.048920000344514845,0.04514000015333295,0.13961891662329434,3.4341769613093605,8.373948113296132,-67.66913735971384,53.619231662805106,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-17,0.05000000074505806,0.05000000074505806,0.049800001084804535,0.049800001084804535,124340,0.0,0.0,0.049500000476837155,0.045490000210702417,0.13694225003321966,0.606061828439296,8.81512474733141,-66.78161765293954,52.27265512823891,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-18,0.05139999836683273,0.05139999836683273,0.047200001776218414,0.049800001084804535,20950,0.0,0.0,0.05014000050723553,0.04582000020891428,0.1338989167784651,-0.6781001575417402,9.428197901842852,-65.78015617204494,52.27265512823891,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-19,0.049800001084804535,0.049800001084804535,0.04600000008940697,0.047200001776218414,304838,0.0,0.0,0.05000000074505806,0.04608500022441149,0.1309589167435964,-5.599997854232821,8.495173053232993,-64.80957435327522,47.75243744401466,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-23,0.04800000041723251,0.04800000041723251,0.041999999433755875,0.042399998754262924,717605,0.0,0.0,0.049360000714659694,0.046140000224113464,0.12756225016588965,-14.100489991139082,6.978761324026626,-63.82942432881967,40.74702571777454,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-24,0.043800000101327896,0.04500000178813934,0.043800000101327896,0.04500000178813934,140849,0.0,0.0,0.049120000749826434,0.046185000240802764,0.12460391679778696,-8.387619907969258,6.354878193614698,-62.93455179602906,45.41797143628204,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-25,0.04500000178813934,0.04500000178813934,0.04500000178813934,0.04500000178813934,46430,0.0,0.0,0.04834000095725059,0.04629000024870038,0.12168725005661447,-6.909389952360515,4.428603796794687,-61.959860028750626,45.41797143628204,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-26,0.04500000178813934,0.04699999839067459,0.0421999990940094,0.04479999840259552,143166,0.0,0.0,0.04758000075817108,0.04642000021412969,0.11906891673182447,-5.84279594635807,2.498924038540395,-61.01417440566783,45.100787162754536,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
2025-06-27,0.04500000178813934,0.04899999871850014,0.04100000113248825,0.04899999871850014,1146552,0.0,0.0,0.047300000488758084,0.04658000022172928,0.11614391667147478,3.5940765585110217,1.5457283460744418,-59.89458461824937,52.58872465604135,,,0.0,0.0,,,24.499998,,Gabather AB (publ),Healthcare,"Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden."
